The Ascent and Descent of Man: What Urological Problems Can Teach Us About Being Men

When the body interrupts the life we thought we were living

Men spend a remarkable amount of their lives trying to move upward.

We grow up. We become stronger. We learn. We compete. We establish careers, relationships and families. We accumulate skills, responsibilities, possessions and, hopefully, a little wisdom along the way.

We build an identity.

Then, sometimes quite unexpectedly, life introduces the downward staircase.

A prostate cancer diagnosis. Erectile dysfunction. Urinary leakage after prostate surgery. An enlarged prostate. Infertility. Testicular cancer. Chronic pelvic pain. A catheter. The discovery that our bladder has apparently developed its own personality.

Suddenly the body that we hardly thought about has become impossible to ignore.

For many men, a health problem is therefore more than a medical diagnosis. It can challenge masculinity, independence, sexuality, confidence, relationships and our assumptions about ageing.

The writings of Franciscan priest and spiritual teacher Richard Rohr offer an interesting way of understanding this experience.

Rohr suggests that human development is not simply a continuous climb towards greater success, control and independence. Paradoxically, some of our deepest development may begin when that climb is interrupted.

Sometimes we grow by descending.

And sometimes what initially feels like falling down becomes a way of falling upward.


Who is Richard Rohr?

Richard Rohr is an American Franciscan friar, Catholic priest, author and ecumenical spiritual teacher. He founded the Center for Action and Contemplation (CAC) in Albuquerque, New Mexico, in 1987 and has spent decades teaching about Christian spirituality, contemplation, human development and transformation.

His books include Everything Belongs, Breathing Under Water, The Universal Christ, Immortal Diamond and perhaps most relevant to this discussion, Falling Upward: A Spirituality for the Two Halves of Life.

Rohr has also devoted considerable attention to male spirituality and the formation of men. His work has resonated with men trying to understand identity, fatherhood, vulnerability, ageing, suffering and what it means to mature beyond achievement and status.

His significance does not lie in providing medical or psychological theories. He is a spiritual teacher.

Rather, Rohr gives us a language for something medicine sees every day:

A man can be physically diminished by an experience while simultaneously becoming deeper because of it.


The Two Halves of Life

One of Rohr’s best-known ideas is that life contains what he calls the two halves of life.

These are not simply determined by age.

You do not automatically enter the second half of life on your 50th birthday, preferably after receiving a letter from your superannuation fund and discovering your prostate has doubled in size.

They describe different ways of understanding ourselves.

In the first half of life, our task is largely to construct an identity.

We establish:

  • Who am I?
  • What do I believe?
  • Where do I belong?
  • What am I good at?
  • What can I achieve?
  • How do other people see me?
  • Can I provide for myself and my family?

Rohr describes this as constructing the container of our lives.

And it is necessary.

Young men need ambition, boundaries, confidence, competence and identity.

The problem arises when we mistake the container for its contents.

At some point the deeper question becomes:

What was I building all of this for?

Rohr describes the movement from the outer task towards this deeper inner task as characteristic of the second half of life. Importantly, this transition is not necessarily connected with chronological ageing.


The Ascent

The first part of life is often an ascent.

A boy becomes a man.

He develops strength and independence.

He studies.

He works.

He competes.

He finds a partner.

Perhaps he becomes a father.

He builds a career.

He becomes responsible for others.

There is nothing inherently wrong with this ascent.

Quite the opposite.

We need it.

The difficulty comes when our entire identity becomes attached to the things we have accumulated during the climb:

strength, sexual performance, status, productivity, physical appearance, money, professional success and control.

Then something happens.

Life refuses to follow the script.


The Descent

The descent may come through failure, divorce, bereavement, redundancy, ageing, disappointment or illness.

For many men, it comes through the body.

And this is where urology becomes surprisingly relevant.

Consider the man diagnosed with prostate cancer.

Yesterday he was working, exercising, travelling and planning his future.

Today he is discussing cancer staging, continence, erections and survival.

Or the man who develops erectile dysfunction.

Something that previously happened almost without thought suddenly requires tablets, injections, devices or surgery.

Or the man who leaks urine following prostate surgery.

A highly competent adult who has spent decades being independent may suddenly find himself discussing pads and pelvic-floor exercises.

These experiences can feel humiliating.

They can also expose something deeper.


“I Thought I Was in Control”

One of the hardest lessons illness teaches is remarkably simple:

We are not completely in control.

We can exercise.

We can eat well.

We can attend medical check-ups.

We can stop smoking.

We can monitor our PSA.

All of these things matter.

But none of them gives us a contract guaranteeing perfect health.

Rohr’s spirituality repeatedly returns to the idea that transformation often begins when our usual systems of control stop working. His image of “falling upward” describes the possibility that failure, suffering or loss can open a person to a broader and deeper understanding of life.

That does not mean illness is good.

Cancer is not a gift that someone ought to be grateful for.

Incontinence is not spiritually necessary.

Erectile dysfunction does not automatically make anyone wiser.

Suffering can simply hurt.

The important distinction is this:

We do not always choose what happens to us, but over time we may have some choice about what we allow the experience to teach us.


Urological Illness Strikes at Some Particularly Male Vulnerabilities

Urology deals with parts of the body closely connected with masculine identity.

The penis.

The testes.

The prostate.

Sexual function.

Fertility.

Urinary control.

Because of this, relatively small physical changes can have enormous psychological consequences.

A man may quietly interpret erectile dysfunction as:

“I am no longer a real man.”

He may interpret urinary leakage as:

“I have lost control.”

Infertility may become:

“I have failed.”

Prostate cancer may become:

“My body has betrayed me.”

After surgery he may think:

“My partner won’t see me in the same way.”

These conclusions can be far more damaging than the physical problem itself.

Part of good urological care is therefore separating the condition a man has from the man he believes he has become because of it.


Your Penis Is Important. It Is Not Your Entire Biography.

Men can attach an extraordinary amount of identity to sexual performance.

This is understandable.

Sexuality matters.

Intimacy matters.

Erections matter.

But erectile function is not a reliable measurement of masculinity.

An erection is a complicated neurovascular event involving the brain, nerves, blood vessels, hormones and psychological state.

It is physiology.

It is not a character reference.

A man can have erectile dysfunction and remain masculine, attractive, intimate, loving and sexually connected.

Likewise, losing a testicle does not make someone half a man.

Needing continence pads does not make someone childish.

Having prostate surgery does not remove masculinity.

And asking for help certainly does not diminish it.

These distinctions can be surprisingly difficult when we have spent decades unconsciously linking masculinity with strength, independence and sexual capability.


The Body Eventually Invites Every Man Down the Mountain

At 20, the body can feel indestructible.

At 40, it begins occasionally submitting complaints.

At 60, it starts sending formal correspondence.

And eventually most of us discover that ageing is not a design flaw.

Testosterone changes.

Prostates enlarge.

Erections may become less reliable.

Muscle mass decreases.

Bladders become more temperamental.

Recovery takes longer.

The male body gradually teaches a lesson the young man rarely wants to hear:

Strength is temporary.

Rohr’s challenge is not that we should despair about this.

It is that the second journey can lead somewhere the first cannot.

The goal changes from proving ourselves to knowing ourselves.

From achievement towards meaning.

From independence towards interdependence.

From certainty towards curiosity.

From controlling life towards participating in it.


The Descent Can Happen at Any Age

It would be a mistake to think Rohr’s “second half of life” begins only in old age.

A 28-year-old diagnosed with testicular cancer may confront mortality earlier than a healthy 75-year-old.

A young man experiencing infertility may suddenly question assumptions he has held since childhood.

A 40-year-old with erectile dysfunction may confront vulnerability for the first time.

A 55-year-old diagnosed with aggressive prostate cancer may completely reconsider his priorities.

A 70-year-old recovering from surgery may discover a depth of intimacy with his partner that he had never previously allowed.

Chronological age and emotional maturity are not the same thing.

The descent arrives according to its own timetable.


From Independence to Interdependence

Many men are taught:

Deal with it yourself.

This can be useful when a tyre needs changing.

It is considerably less useful when dealing with cancer.

Urological illness often forces men to accept help.

From a partner.

A doctor.

A nurse.

A physiotherapist.

A psychologist.

A friend.

Sometimes even from their children.

This can initially feel like weakness.

But perhaps mature masculinity is not independence.

Perhaps it is knowing when independence has reached its limits.

There is strength in competence.

There is another kind of strength in saying:

“I need some help with this.”


Intimacy After Urological Illness

Urological disease can also change relationships.

After prostate cancer treatment, for example, sexual intimacy may require patience, rehabilitation and experimentation.

Erections may be different.

Orgasm may feel different.

Ejaculation may disappear following prostate removal.

Urinary leakage may temporarily interfere with confidence.

Some couples withdraw from intimacy because neither partner knows how to begin the conversation.

Yet intimacy is much larger than erectile performance.

Touch.

Affection.

Humour.

Conversation.

Vulnerability.

Sexual experimentation.

Companionship.

Trust.

These can become increasingly important when the body no longer behaves exactly as it did at 25.

Paradoxically, some couples discover greater intimacy precisely because they can no longer rely on automatic sexual function.

They have to communicate.

The descent becomes an invitation to a different kind of closeness.


The Man Who Emerges

Rohr’s “falling upward” does not mean returning to exactly the person we were before the fall.

Sometimes we cannot.

The prostate is not coming back after radical prostatectomy.

A removed testicle cannot be restored.

Ageing cannot be reversed.

The challenge becomes something different:

Can I incorporate what has happened into a larger understanding of who I am?

The man who emerges may be less certain but more compassionate.

Less physically powerful but more emotionally available.

Less interested in impressing others.

More comfortable asking difficult questions.

More appreciative of his partner.

More aware of mortality.

More grateful for ordinary days.

Less frightened of appearing vulnerable.

That is not necessarily decline.

It may be maturation.


The Urologist’s Job Is Still to Treat the Problem

There is an important caution here.

Philosophy should never replace medicine.

If you have difficulty urinating, see your doctor.

If you have blood in the urine, have it investigated.

If you discover a testicular lump, seek medical attention promptly.

If erectile dysfunction develops, investigate the possible physical and psychological causes.

If your PSA is abnormal, discuss appropriate assessment.

If you are struggling psychologically following cancer or changes in sexual or urinary function, psychological support can be extremely valuable.

We should never romanticise illness when effective treatment is available.

Treat what can be treated. Rehabilitate what can be rehabilitated. Prevent what can be prevented.

And then recognise that sometimes medicine can repair the body without answering every question the experience has raised.


Perhaps There Is Another Kind of Men’s Health

We usually define men’s health through measurable things:

PSA.

Blood pressure.

Cholesterol.

Testosterone.

Weight.

Urinary flow.

Erectile function.

Cancer survival.

All are important.

But perhaps there is another dimension.

Can a man tolerate vulnerability?

Can he talk to his partner?

Can he ask for help?

Can he adapt when his body changes?

Can he distinguish sexual function from personal worth?

Can he remain connected when embarrassed?

Can he face ageing without believing that ageing makes him irrelevant?

Can he accept mortality without abandoning life?

These questions will never appear on a pathology request form.

But they matter.


From Ascent to Descent and Back Again

Richard Rohr’s Falling Upward proposes that the second half of the human journey can contain profound spiritual richness rather than simply representing decline. His central paradox is that what appears to be a fall may become movement into a larger and deeper life.

Urological illness gives this idea an unexpectedly practical setting.

A prostate cancer diagnosis.

Loss of erections.

Incontinence.

Infertility.

Testicular disease.

Ageing.

These experiences may temporarily take something away.

But they do not take away the person.

For the younger man, the lesson may be that masculinity is broader than performance.

For the middle-aged man, it may be that identity is larger than career, strength and sexuality.

For the older man, it may be discovering that physical decline does not necessarily mean personal decline.

And for every man, perhaps the invitation is similar.

Build.

Climb.

Achieve.

Love your strength while you have it.

But when life eventually asks you to descend, do not automatically assume you are travelling in the wrong direction.

Sometimes the road downward leads somewhere that the road upward could never reach.

Sometimes losing a little control allows us to discover what actually matters.

And sometimes, in Richard Rohr’s memorable language, we discover that we have been falling upward all along.


Richard Rohr’s Work in Australia: Centre for Men and Families

For Australian men interested in exploring these ideas beyond reading, the Centre for Men and Families (CFMF), formerly known as Centre for Men Australia, provides an important local connection to Richard Rohr’s work.

The organisation has supported men and families in Australia for more than 25 years, providing men’s groups, counselling, retreats, community programs and Men’s Rites of Passage (MROP).

Its Men’s Rites of Passage tradition has a direct connection with Richard Rohr and the Center for Action and Contemplation in the United States. The Australian program uses initiation, time in nature, reflection, ritual and the company of other men to explore masculinity, vulnerability, relationships, grief, purpose and the transition towards a more mature understanding of what it means to be a man.

This has particular relevance to the themes discussed in this article. A significant health event, including prostate cancer, loss of erectile function, infertility, incontinence or major surgery, can become an unexpected rite of passage of its own. Medicine treats the disease, but men may also need somewhere to explore what the experience has done to their sense of identity, masculinity, relationships and purpose.

The Centre welcomes men from a wide range of backgrounds and beliefs. Its programs are not limited to men who identify with a particular religious tradition.

Learn more:
Centre for Men and Families Australia

Men’s Rites of Passage:
Explore the Australian Men’s Rites of Passage program

Where Can Men Find Support?

Urological illness can affect much more than the urinary or reproductive system. It can touch confidence, masculinity, sexuality, relationships, identity and our sense of purpose.

Medical care remains essential, but sometimes men also benefit from having a place to talk, reflect and connect with other men.

Centre for Men and Families Australia

The Centre for Men and Families (CFMF), formerly Centre for Men Australia, provides programs designed to support men through different stages and transitions in life.

Through men’s circles, counselling, retreats and Men’s Rites of Passage, men can explore relationships, fatherhood, vulnerability, ageing, loss, purpose and what mature masculinity might look like when life does not follow the expected script.

Explore the Centre for Men and Families:
https://cfmf.org.au/

Men’s Rites of Passage:
https://cfmf.org.au/events/rites-of-passage/

For a man facing prostate cancer, erectile dysfunction, infertility, incontinence, major surgery or another significant health challenge, asking for support is not an admission of failure.

Sometimes the most important part of the journey is discovering that you do not have to make the descent alone.

Further reading

Richard Rohr, Falling Upward: A Spirituality for the Two Halves of Life.

Richard Rohr, Adam’s Return: The Five Promises of Male Initiation.

Richard Rohr, Immortal Diamond: The Search for Our True Self.

Richard Rohr, The Universal Christ.

The Center for Action and Contemplation provides further material on Rohr’s teachings concerning contemplation, male spirituality, transformation and the two halves of life.

Medical disclaimer

This article discusses the emotional, philosophical and spiritual dimensions that may accompany men’s health problems. It is not intended to suggest that illness is desirable or that spiritual reflection is a substitute for medical or psychological treatment. New or concerning urinary, genital or sexual symptoms should be assessed by an appropriately qualified healthcare professional.

The Female Orgasm: A Guide for Men Who Would Like to Understand It Better

Different equipment. Different wiring. Different timetable.

One of the more useful things a man can learn about female sexuality is surprisingly simple:

A woman’s orgasm is not just the female version of a man’s orgasm.

There are important similarities, but the anatomy, nerve pathways, sexual response and psychological influences can be quite different.

For many men, sexual arousal follows a relatively predictable path: stimulation → erection → increasing excitement → ejaculation and orgasm → recovery.

Female sexual response is often less linear. Arousal may build gradually, disappear, return, plateau for a while, suddenly accelerate or occasionally decide that tonight it has other plans.

Understanding this difference can remove a great deal of unnecessary pressure from both partners. So, guys take notes.


What exactly is a female orgasm?

An orgasm is an intense neurological and muscular response occurring at the peak of sexual arousal.

It involves coordinated activity between:

  • the brain
  • sensory nerves
  • the spinal cord
  • the clitoris and surrounding genital tissues
  • the pelvic floor muscles
  • the autonomic nervous system
  • hormones and neurotransmitters
  • emotional and psychological responses

During orgasm, there are usually rhythmic contractions of the pelvic floor muscles together with an intense sensation of pleasure and release.

Some women describe a very obvious peak. Others describe a spreading wave of pleasure, warmth, pulsation or relaxation.

There is considerable normal variation.


Gentlemen, Meet the Clitoris

If there is one piece of anatomy worth understanding, this is it.

The clitoris is the principal organ responsible for female orgasm.

And it is considerably larger than the small structure visible externally.

The visible portion, called the glans clitoris, is only the tip of a much larger erectile organ. Internally, the clitoris extends around the vaginal opening through paired structures known as the crura and vestibular bulbs.

During sexual arousal these tissues become engorged with blood.

In other words, female genital anatomy contains erectile tissue too.

The penis and clitoris actually develop from related embryological tissues.

They are relatives, although they have subsequently pursued rather different careers.


Isn’t orgasm caused by vaginal penetration?

Sometimes.

But this is one of the most persistent misunderstandings about female sexuality.

Many women do not reliably orgasm from vaginal penetration alone.

For many women, direct or indirect clitoral stimulation is the most reliable route to orgasm.

During intercourse, movement may indirectly stimulate the clitoris and its surrounding internal structures. For some women this produces orgasm easily. For others, additional clitoral stimulation is required.

Neither response is abnormal.

A woman who requires clitoral stimulation to orgasm does not have a sexual dysfunction simply because penetration alone is insufficient.

That is anatomy, not failure.


What About the “G-Spot”?

The so-called G-spot remains an area of scientific discussion.

Some women report intense sensitivity along the anterior wall of the vagina. This region lies close to the urethra, periurethral glands and internal components of the clitoral complex.

Rather than necessarily being a completely separate “orgasm button”, some researchers consider this area part of a broader interconnected clitoral-urethral-vaginal anatomical complex.

More importantly, women vary enormously in what feels pleasurable.

There is no secret anatomical combination that somebody has forgotten to tell men about.


The Brain May Be the Most Important Sexual Organ

Genital stimulation sends sensory signals through peripheral nerves to the spinal cord and brain.

But the brain does considerably more than simply receive those signals.

Sexual arousal can be influenced by:

desire + sensation + attention + emotional connection + relaxation + stimulation + context

At the same time, competing signals can interfere:

stress + anxiety + pain + distraction + relationship difficulties + fear + self-consciousness + medications

This helps explain something men sometimes find confusing.

A woman can be physically stimulated but not sufficiently aroused to orgasm.

Conversely, strong psychological arousal can greatly amplify relatively modest physical stimulation.

The nervous system is not simply an electrical cable running from the genitals to the brain. The brain is actively interpreting what is happening.


Female Arousal Often Needs Time

Male sexual response can sometimes move from “nothing much happening” to “fully operational” with impressive efficiency.

Female arousal frequently develops more gradually.

As arousal increases:

  • blood flow to the genital tissues increases
  • the clitoris becomes engorged
  • vaginal lubrication usually increases
  • genital sensitivity changes
  • the pelvic floor becomes increasingly active
  • heart rate and breathing increase
  • mental focus on sexual stimulation may intensify

The amount of stimulation required varies enormously between women and even within the same woman on different occasions.

Age, fatigue, hormonal status, medications, stress and relationship circumstances can all influence the response.

So there is no medically correct number of minutes before a woman “should” orgasm.


Is There Such a Thing as a Normal Female Orgasm?

Yes.

Actually, there are lots of normal female orgasms.

Some are intense.

Some are subtle.

Some involve obvious pelvic contractions.

Some feel more like a prolonged wave of pleasure.

Some women orgasm quickly.

Others require prolonged stimulation.

Some can experience several orgasms relatively close together.

Others experience one and then lose interest in further stimulation.

And some women do not orgasm every time they have sex.

All of these can fall within normal sexual experience.

Frequency is not a scorecard.


Multiple Orgasms: Fact or Fiction?

They are real, but they are certainly not compulsory.

Men commonly experience a refractory period after ejaculation during which another erection or orgasm may be difficult or impossible for a period of time.

Women do not necessarily have the same physiological refractory period.

Some therefore remain highly aroused after orgasm and can experience another orgasm with continued stimulation.

Others become extremely sensitive after orgasm and want stimulation to stop immediately.

Again, both are normal.


Orgasm and Ejaculation Are Not the Same Thing

For men, ejaculation and orgasm usually occur together, which makes it tempting to think they are essentially the same event.

They are not.

Even in men they are separate physiological processes that usually happen almost simultaneously.

In women, orgasm does not require ejaculation.

Some women experience the release of fluid during intense sexual stimulation or orgasm. This may arise from periurethral glands, the bladder or a combination of sources.

It is not necessary for orgasm and its absence means absolutely nothing about the quality of the sexual experience.


Why Might a Woman Have Difficulty Reaching Orgasm?

Difficulty reaching orgasm is common.

When persistent and distressing, it may be referred to as female orgasmic disorder or anorgasmia.

Possible contributors include:

Psychological factors

Stress, anxiety, depression, previous negative sexual experiences, body-image concerns, performance anxiety and difficulty relaxing can interfere with orgasm.

Relationship factors

Poor communication, unresolved conflict, lack of emotional intimacy or simply not communicating what type of stimulation feels pleasurable can contribute.

Medications

Certain medications can substantially delay or prevent orgasm.

Antidepressants, particularly SSRIs and SNRIs, are well-known examples.

Some other psychiatric medications and medications affecting the nervous system may also contribute.

Menopause and hormonal changes

Reduced oestrogen levels can contribute to vaginal dryness, discomfort and changes in genital sensitivity.

The hormonal transition around menopause can also influence desire and arousal.

Pain

Sex should not routinely hurt.

Vaginal dryness, vulval conditions, pelvic floor muscle problems, endometriosis, infections and other pelvic disorders can make sexual activity painful.

Pain is a remarkably effective way of telling the brain:

“Perhaps orgasm is not today’s priority.”

Neurological conditions

Damage or disease affecting the brain, spinal cord or peripheral nerves may alter genital sensation and orgasm.

This can occur with conditions such as multiple sclerosis, spinal cord disease, pelvic nerve injury and some forms of neuropathy.

Pelvic surgery

Operations involving the pelvis may occasionally alter sensation, anatomy or sexual response.


An Important Lesson for Men: More Effort Isn’t Always the Answer

When something is not working, the instinctive male response can be:

Try harder.

Unfortunately, sexual physiology doesn’t always reward enthusiasm with increased horsepower.

Too much pressure, speed or intensity can actually become uncomfortable and reduce arousal.

Female orgasm often depends more on appropriate stimulation than simply more stimulation.

Communication is therefore considerably more useful than guesswork.


Don’t Turn Orgasm Into an Examination

One of the quickest ways to make orgasm more difficult is to make it compulsory.

Questions such as:

“Are you close?”

“Why aren’t you coming?”

“Did you?”

may be well intentioned, but they can suddenly transform an intimate experience into something resembling a practical driving test.

Performance anxiety activates precisely the mental processes that can interfere with sexual arousal.

Orgasm is much easier when it is allowed to happen rather than being monitored.


The Orgasm Gap

Research has repeatedly identified differences in orgasm frequency between heterosexual men and women.

This does not mean that female orgasm is inherently difficult.

Part of the difference probably reflects misunderstandings about female anatomy and the tendency to make vaginal penetration the central measure of sexual activity despite the importance of the clitoris.

Learning the anatomy, communicating and allowing sufficient arousal can make a considerable difference.


What Can Partners Do?

Perhaps the most useful principle is:

Be curious rather than assuming.

Every woman’s sexual response is different.

Partners can help by:

  • allowing sufficient time for arousal
  • recognising the importance of clitoral stimulation
  • asking rather than guessing what feels pleasurable
  • varying pressure, rhythm and stimulation according to feedback
  • avoiding making orgasm the compulsory endpoint
  • addressing vaginal dryness or pain
  • maintaining emotional intimacy and communication
  • recognising that stress and fatigue matter
  • remembering that what worked perfectly last time may not necessarily be today’s preferred formula

Sexual communication may initially feel awkward.

It usually becomes considerably easier once both partners realise they are on the same team.


Does a Woman Need to Orgasm for Sex to Be Successful?

No.

Orgasm can be an important and pleasurable part of sexual intimacy, but it does not need to occur during every sexual encounter.

Pleasure, intimacy, affection and connection can all exist without orgasm.

The difficulty arises when a woman wants to orgasm but persistently cannot, particularly if this is causing distress to her or affecting the relationship.

That deserves assessment rather than embarrassment.


When Should Medical Advice Be Considered?

A woman should consider discussing the issue with her GP, gynaecologist, sexual-health clinician or appropriately trained specialist if there is:

  • a persistent inability to orgasm that causes distress
  • a significant change from her previous sexual function
  • reduced genital sensation
  • pain during sexual activity
  • vaginal dryness or menopausal symptoms
  • neurological symptoms
  • difficulty following pelvic surgery
  • concern that medication is affecting sexual function

Treatment depends on the cause.

It may involve education, medication review, treatment of vaginal dryness or hormonal problems, pelvic floor physiotherapy, psychological or psychosexual therapy, treatment of underlying medical conditions and, importantly, helping a woman and her partner understand her individual sexual response.


A Final Message for Men

The female orgasm isn’t a complicated version of the male orgasm.

It is its own physiological process.

The clitoris matters enormously. The brain matters enormously. Time, comfort, communication and psychological context matter too.

Perhaps the most important lesson is that there is no universal technique and no required timetable.

Female sexuality varies between women and within the same woman throughout her life.

Understanding that difference can take considerable pressure off both partners.

And if you are wondering whether listening, communication and understanding anatomy really matter more than trying to perform some secret advanced manoeuvre…

Yes. They do.

Sometimes good sex begins not with knowing exactly what to do, but with being comfortable enough to ask.

Delayed Ejaculation: When Getting There Takes Longer Than Expected

Delayed ejaculation is a male sexual difficulty in which it takes an unusually long time to reach orgasm and ejaculate, or ejaculation does not occur at all, despite adequate sexual stimulation and the desire to climax.

There is no stopwatch that defines what is “normal”. Some men naturally take longer than others. Delayed ejaculation becomes a problem when the delay is persistent, causes frustration or distress, interferes with sexual enjoyment, or affects a relationship.

At the extreme end of the spectrum, a man may be unable to ejaculate at all. This is known as anejaculation.

The important message is that delayed ejaculation is a genuine sexual health problem. It is often caused by several factors acting together, and in many men it can be improved.

How Long Is Too Long?

There is no universally accepted time limit.

Some clinical definitions have suggested ejaculation taking approximately 25–30 minutes or longer, but time alone does not make the diagnosis.

A man who takes 30 minutes and is perfectly happy may not have a problem. Another man who previously ejaculated within 5–10 minutes and now cannot reach orgasm despite prolonged stimulation may be considerably distressed.

The more useful question is:

“Is ejaculation taking substantially longer than you would like, or have you become unable to ejaculate when you want to?”

Delayed ejaculation may be:

Lifelong – the difficulty has been present since the beginning of a man’s sexual life.

Acquired – ejaculation was previously normal but has become progressively or suddenly more difficult.

It may also be:

Generalised – occurring during masturbation as well as partnered sexual activity.

Situational – occurring only in particular circumstances. For example, a man may be able to orgasm during masturbation but struggle during intercourse.

That distinction can provide an important clue to the underlying cause.


Ejaculation Is More Complicated Than It Looks

Ejaculation is not simply a penile reflex.

Successful orgasm and ejaculation require cooperation between the:

  • brain
  • spinal cord
  • autonomic nervous system
  • sensory nerves from the penis
  • pelvic floor muscles
  • prostate and seminal tract
  • hormones
  • erectile response
  • psychological state
  • sexual stimulation and arousal

Think of it as a rather complicated neurological relay race. If one runner slows down, the finish line may suddenly become surprisingly difficult to reach.


What Causes Delayed Ejaculation?

Frequently there is more than one contributing factor.

Medications

Medication is one of the most important reversible causes.

Particular attention should be given to antidepressants, especially selective serotonin reuptake inhibitors (SSRIs) and related medications. These drugs can be extremely effective treatments for depression and anxiety but may significantly delay orgasm and ejaculation.

Other medications that may contribute include certain:

  • antidepressants
  • antipsychotics
  • anti-anxiety medications
  • opioid pain medications
  • blood pressure medications
  • alpha-blockers
  • medications acting on the central nervous system

If the problem started after beginning a new medication or increasing its dose, this is worth discussing with your doctor.

Do not stop antidepressants or other prescribed medications suddenly. Medication changes should be discussed with the prescribing doctor.


Ageing and Reduced Penile Sensation

Ejaculation often takes longer with increasing age.

Changes can include reduced penile sensitivity, slower nerve transmission, altered erectile quality and a greater amount of stimulation being required to achieve orgasm.

This does not mean that satisfactory sexual function has an expiry date. It may simply mean that the stimulation that worked at 30 may need some renovation at 60 or 70.


Diabetes and Nerve Problems

Ejaculation depends heavily on normal nerve function.

Conditions that can interfere with these pathways include:

  • diabetes
  • diabetic neuropathy
  • multiple sclerosis
  • spinal cord disease or injury
  • pelvic nerve injury
  • previous major pelvic surgery
  • neurological disorders

Diabetes is particularly important because long-standing elevated blood glucose can damage the small autonomic and sensory nerves involved in erection, orgasm and ejaculation.


Hormonal Causes

Hormonal abnormalities occasionally contribute to delayed ejaculation or reduced orgasmic intensity.

These may include:

  • testosterone deficiency
  • thyroid abnormalities
  • prolactin disorders

Low testosterone is more commonly associated with reduced sexual desire and arousal than isolated delayed ejaculation, but hormone testing may be appropriate when other symptoms are present.


Erectile Dysfunction

Erectile dysfunction and delayed ejaculation frequently overlap.

A man may be able to obtain an erection but gradually lose rigidity during prolonged intercourse. Attention then shifts from sexual pleasure to maintaining the erection:

“Am I losing it?”

That thought alone can interrupt arousal.

Treatment of associated erectile dysfunction can therefore sometimes make ejaculation easier.


Psychological and Relationship Factors

The brain is one of the most important sexual organs involved in ejaculation.

Stress, anxiety, depression and relationship difficulties can all interfere with the normal progression from sexual stimulation to arousal, orgasm and ejaculation.

Common contributors include:

  • performance anxiety
  • relationship conflict
  • fear of disappointing a partner
  • previous negative sexual experiences
  • depression
  • general anxiety
  • excessive concentration on “trying to finish”
  • reduced attraction or sexual excitement
  • difficulty communicating sexual preferences
  • cultural or religious inhibition surrounding sexuality

A particularly frustrating cycle can develop:

Difficulty ejaculating → trying harder → increased pressure → reduced arousal → even greater difficulty ejaculating.

Sex begins to feel like an examination rather than an experience.

Breaking that cycle can be an important part of treatment.


Masturbation Style and Sexual Conditioning

This is worth discussing openly because it is surprisingly common.

Some men develop a very specific masturbation technique involving a particular:

  • pressure
  • speed
  • grip
  • position
  • fantasy
  • visual stimulus

The nervous system becomes accustomed to that very specific form of stimulation.

Partnered sexual activity may then provide a different type or intensity of stimulation, making orgasm considerably more difficult.

This does not mean masturbation is harmful.

Rather, the issue may be a mismatch between the stimulation the brain has learned to associate with orgasm and the stimulation occurring during partnered sex.

Changing masturbation technique, reducing excessive pressure and introducing greater variation may help.


Alcohol and Recreational Drugs

Small amounts of alcohol may reduce inhibition, but larger quantities can impair:

  • erection
  • penile sensation
  • arousal
  • orgasm
  • ejaculation

Reducing excessive alcohol intake may therefore improve sexual function.


Previous Pelvic or Prostate Surgery

Operations involving the prostate, bladder neck, pelvis or retroperitoneal nerves can alter ejaculation.

It is important, however, to distinguish delayed ejaculation from retrograde ejaculation or dry orgasm.

Following some prostate procedures, semen may travel backwards into the bladder rather than forwards through the penis.

Following radical prostatectomy, the prostate and seminal vesicles have been removed, so semen is no longer produced and ejaculation cannot occur, although orgasm may still be possible.

These are different conditions and require different counselling.


How Does Delayed Ejaculation Affect a Man?

The physical problem is only part of the story.

Men may experience:

  • frustration
  • reduced sexual confidence
  • performance anxiety
  • avoidance of sexual activity
  • reduced enjoyment of sex
  • difficulty achieving orgasm
  • exhaustion during prolonged intercourse
  • erection loss before ejaculation
  • concerns about masculinity
  • fertility difficulties

Some men eventually avoid intimacy because they anticipate another unsuccessful attempt.

That can allow a sexual problem to become a relationship problem.


How Does It Affect a Partner?

Delayed ejaculation can also be difficult for partners.

A partner may incorrectly wonder:

“Does he still find me attractive?”

or:

“Am I doing something wrong?”

Prolonged intercourse can also become physically uncomfortable or exhausting.

Partners may experience:

  • frustration
  • reduced sexual confidence
  • feelings of rejection
  • concern about attractiveness
  • anxiety about sexual performance
  • vaginal discomfort from prolonged intercourse
  • reduced intimacy
  • relationship tension

This is why communication is so important.

Delayed ejaculation usually should not be interpreted as a measure of attraction, love or the quality of a relationship.


Fertility

Delayed ejaculation can create difficulty when attempting to conceive, particularly when ejaculation cannot occur during vaginal intercourse.

Depending on the cause, options may include collecting semen through masturbation, penile vibratory stimulation or, in selected cases, assisted reproductive techniques.

Men experiencing fertility problems should discuss this specifically with their urologist or fertility specialist.


How Is Delayed Ejaculation Investigated?

The most important investigation is often a good conversation.

Your urologist may ask about:

  • when the problem began
  • whether it occurs every time
  • ejaculation during masturbation
  • ejaculation during intercourse
  • orgasmic sensation
  • penile sensation
  • erectile function
  • libido
  • medications
  • alcohol and recreational drugs
  • diabetes and neurological conditions
  • previous pelvic or prostate surgery
  • psychological wellbeing
  • relationship factors
  • masturbation habits and sexual stimulation

A focused physical examination may also be appropriate.

Blood tests may include, where clinically indicated:

  • testosterone
  • blood glucose or HbA1c
  • thyroid function
  • prolactin
  • other metabolic investigations

Not every man requires every test. Investigation should be directed by the history.


Can Delayed Ejaculation Be Treated?

Yes, but treatment needs to target the cause.

There is no single tablet that reliably “switches ejaculation back on”.

Management is therefore usually individualised.

1. Review Medications

This is one of the first steps.

If symptoms began after starting an antidepressant or another medication, the prescribing doctor may consider:

  • reducing the dose
  • changing medication
  • altering the treatment regimen
  • substituting an alternative drug

This should always be done under medical supervision.


2. Improve Sexual Stimulation

Sometimes the simplest changes are surprisingly useful.

Experimenting with different:

  • sexual positions
  • stimulation techniques
  • pace
  • pressure
  • manual stimulation
  • oral stimulation
  • vibratory stimulation
  • sexual settings

may increase arousal sufficiently to trigger orgasm.

The goal is not necessarily more stimulation. It is finding the right stimulation.


3. Modify Masturbation Technique

If orgasm is easy during masturbation but difficult with a partner, consider whether masturbation provides a type of stimulation that partnered sex cannot reproduce.

Reducing grip pressure, changing technique and introducing greater variety can sometimes help retrain the sexual response.


4. Penile Vibratory Stimulation

A penile vibrator can provide strong, consistent sensory stimulation and may be useful for selected men, particularly those with reduced penile sensation or neurological impairment.

This can sometimes be incorporated into partnered sexual activity rather than being viewed purely as a medical device.


5. Treat Erectile Dysfunction

If maintaining an erection is part of the problem, treating erectile dysfunction may improve the overall sexual response.

Depending on the individual, this may include lifestyle modification, oral erectile medications or other erectile dysfunction treatments.


6. Address Hormonal Problems

Testosterone replacement may be appropriate when genuine testosterone deficiency has been demonstrated and the patient has compatible symptoms.

Testosterone should not simply be prescribed as a general treatment for delayed ejaculation when testosterone levels are normal.


The Role of Psychology and Sex Therapy

Psychological input can be extremely valuable.

This does not mean the problem is imaginary.

Sexual function sits at the intersection of neurology, hormones, physical sensation, emotion, attention and relationships. Treating only one component can sometimes miss half the picture.

A psychologist or sex therapist experienced in sexual medicine can help address:

  • performance anxiety
  • excessive focus on ejaculation
  • relationship difficulties
  • communication
  • sexual expectations
  • anxiety or depression
  • sexual inhibition
  • mismatched sexual stimulation
  • problematic sexual conditioning

Couples-based therapy can be particularly useful because delayed ejaculation frequently affects both partners.

One important therapeutic goal is to shift the focus away from:

“I have to ejaculate.”

and back towards:

“We are here to enjoy sexual intimacy.”

Paradoxically, removing the pressure to orgasm can sometimes make orgasm considerably easier.


Are There Medications Specifically for Delayed Ejaculation?

At present, there is no medication with strong evidence as a universally effective treatment for delayed ejaculation.

A number of medications have been investigated or used off-label, including drugs that influence dopamine, serotonin and other neurotransmitter systems.

However, evidence for these treatments remains limited and inconsistent.

For this reason, medication should generally be considered only after identifying and addressing reversible causes, and patients should understand the limitations and potential side effects.

Be cautious of internet advertisements promising a guaranteed pharmaceutical cure. Ejaculation has unfortunately not yet been reduced to an on/off button.


What Can I Do to Improve It?

A practical starting plan is:

  1. Review your medications with your doctor.
  2. Check for erectile dysfunction, diabetes, neurological or hormonal problems.
  3. Reduce excessive alcohol consumption.
  4. Stop timing yourself. Sexual performance is not an Olympic event.
  5. Discuss the problem openly with your partner.
  6. Experiment with different stimulation and sexual positions.
  7. Consider modifying a very intense or repetitive masturbation technique.
  8. Consider vibratory stimulation if additional penile stimulation is helpful.
  9. Address anxiety, stress and relationship issues.
  10. Consider psychosexual or couples therapy when psychological or relationship factors are contributing.

When Should I See a Urologist?

Consider seeking assessment if:

  • ejaculation has become substantially slower than previously
  • you frequently cannot ejaculate
  • you can ejaculate during masturbation but not with a partner
  • orgasm has become weaker or absent
  • penile sensation has changed
  • you have associated erectile dysfunction
  • symptoms began after medication changes
  • you have diabetes or neurological disease
  • the problem is affecting your relationship
  • you are trying to conceive

A sudden unexplained change in sexual function deserves medical assessment rather than simply being attributed to ageing.


Is There Hope?

Absolutely.

Delayed ejaculation can be frustrating precisely because the solution is not always a single medication or procedure. But that also means there are often several areas in which improvement can be made.

For some men, changing a medication makes a dramatic difference. For others, treating erectile dysfunction, improving penile stimulation, changing masturbation habits or addressing testosterone deficiency helps.

For many men, the greatest improvement comes from combining physical treatment with psychosexual strategies and better communication between partners.

The aim is not necessarily to achieve ejaculation within a particular number of minutes.

The aim is to restore pleasure, confidence, intimacy and control.

If ejaculation has become difficult, excessively delayed or impossible, speak with your GP, urologist or sexual medicine specialist. A careful assessment can often identify contributing factors and provide a pathway towards improvement.

This information is intended for general patient education and does not replace individual medical advice.

 

Journal of Urology AUA Guideline Article1 Mar 2022

Disorders of Ejaculation: An AUA/SMSNA Guideline

Anorgasmia: When Orgasm Becomes Difficult or Impossible

Is there hope? Absolutely.

Anorgasmia is the inability, or persistent difficulty, to reach orgasm despite sexual stimulation and arousal that would normally be expected to produce one.

For some people, orgasm has never occurred. For others, it was previously normal but has gradually or suddenly become difficult or impossible.

Although anorgasmia can be frustrating, confusing and sometimes distressing for both the individual and their partner, it is important to understand one thing from the outset:

Anorgasmia does not necessarily mean that something is permanently damaged, and in many cases there are identifiable and potentially treatable contributing factors.

Orgasm is not simply a genital reflex. It involves the brain, spinal cord, peripheral nerves, hormones, emotions, attention, sexual stimulation and relationship context. If one part of this rather complicated orchestra is playing from the wrong sheet of music, the finale may not arrive.


What is an orgasm?

Orgasm is a complex neurological and physiological event involving the brain, spinal cord, pelvic nerves and genital organs.

In men, orgasm usually occurs at approximately the same time as ejaculation, but orgasm and ejaculation are actually separate processes. A man may therefore:

  • ejaculate with little or no pleasurable orgasm;
  • experience orgasm without normal ejaculation;
  • have markedly delayed orgasm; or
  • be unable to achieve orgasm at all.

Similarly, women may experience normal desire and arousal but have considerable difficulty reaching orgasm.

Anorgasmia can therefore affect both men and women.


Different Types of Anorgasmia

Understanding the pattern can provide important clues about its cause.

Lifelong or primary anorgasmia

The person has never experienced an orgasm.

Acquired or secondary anorgasmia

Orgasm was previously possible but has subsequently become difficult or impossible.

This is particularly important because a new change may be associated with medication, surgery, neurological disease, hormonal changes, psychological factors or changes within a relationship.

Generalised anorgasmia

Orgasm cannot be achieved under virtually any circumstances, including masturbation and partnered sexual activity.

Situational anorgasmia

Orgasm occurs in some circumstances but not others.

For example, someone may be able to reach orgasm during masturbation but not during intercourse, or with one form of stimulation but not another.

This distinction is often extremely helpful.


What Causes Anorgasmia?

There is rarely a single universal cause.

Anorgasmia is best approached as a biological, neurological, hormonal, medication-related and psychological condition rather than assuming that the problem is entirely physical or entirely “in the mind.”

1. Medications

Medication is one of the most important potentially reversible causes.

Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are well recognised for causing delayed orgasm or anorgasmia.

Other medications may also interfere with sexual function, including some:

  • antidepressants;
  • antipsychotic medications;
  • medications used for anxiety;
  • blood pressure medications;
  • medications affecting hormonal pathways; and
  • other drugs acting on the central nervous system.

If the problem appeared after starting a new medication or increasing its dose, this is worth discussing with your doctor.

Do not stop prescribed medication suddenly simply because sexual side effects have developed. There may be alternatives, dose adjustments or other strategies available.


2. Previous Pelvic or Prostate Surgery

For men, anorgasmia or significant changes in orgasm can occasionally occur following pelvic surgery.

This may include:

  • radical prostatectomy;
  • prostate surgery;
  • bladder surgery;
  • colorectal or pelvic surgery; and
  • surgery affecting pelvic nerves.

After radical prostatectomy, for example, ejaculation is no longer possible because the prostate and seminal vesicles have been removed and the reproductive tract has been disconnected.

However, this does not automatically mean that orgasm is impossible.

Many men remain capable of experiencing a “dry orgasm” following prostatectomy, although the sensation may feel different from what they experienced before surgery.


3. Neurological Causes

Orgasm depends heavily on intact nerve pathways between the genitalia, spinal cord and brain.

Conditions that may interfere with these pathways include:

  • diabetes;
  • multiple sclerosis;
  • spinal cord injury;
  • peripheral neuropathy;
  • pelvic nerve injury; and
  • some neurological diseases.

Reduced genital sensation can make orgasm considerably more difficult even when erections and sexual desire remain relatively intact.


4. Hormonal Factors

Hormonal abnormalities can sometimes contribute to orgasmic dysfunction.

Depending upon the individual circumstances, assessment may include consideration of:

  • testosterone;
  • prolactin;
  • thyroid function; and
  • other hormonal abnormalities.

Low testosterone is particularly relevant when anorgasmia occurs together with reduced libido, fatigue or erectile difficulties.

Hormone testing is not necessarily required for everyone and should be guided by the history and clinical findings.


5. Erectile Dysfunction and Reduced Arousal

Sometimes the apparent inability to orgasm is actually downstream from another sexual difficulty.

For example, a man may have an erection sufficient for penetration but insufficiently firm or sustained to generate the stimulation necessary to reach orgasm.

Treating associated erectile dysfunction may therefore improve orgasmic function. Current AUA guidance recommends addressing coexisting erectile dysfunction appropriately in men with delayed ejaculation.


6. Alcohol and Recreational Drugs

Alcohol may reduce anxiety in small quantities, but excessive alcohol can blunt genital sensation and interfere with the neurological processes required for orgasm.

Recreational drugs may similarly affect sexual desire, erections, sensation and orgasm.


7. Changes in Sexual Stimulation

Sometimes there is nothing structurally wrong at all.

A person’s nervous system may simply have become accustomed to a particular pattern, pressure, speed or intensity of stimulation during masturbation that is difficult to reproduce during partnered sex.

This can produce the rather puzzling situation of:

“Everything works perfectly on my own, but not with my partner.”

That distinction is useful rather than embarrassing because it suggests that the orgasm pathway itself is functioning.

Treatment may involve changing masturbation technique, varying stimulation and gradually allowing the nervous system to respond to a broader range of sexual sensations.


The Psychological Component

Psychology is not an afterthought in the management of anorgasmia.

The brain is arguably our most important sexual organ.

Orgasm requires a peculiar combination of stimulation, attention and letting go. Trying intensely to make an orgasm happen can sometimes make it less likely to occur.

Performance anxiety can create a frustrating cycle:

Difficulty reaching orgasm → worrying about orgasm → trying harder → monitoring performance → increasing anxiety → even greater difficulty reaching orgasm.

Eventually sex can begin to feel less like intimacy and more like an examination with an inconveniently unpredictable pass mark.

Psychological contributors may include:

  • performance anxiety;
  • stress;
  • depression;
  • general anxiety;
  • relationship difficulties;
  • fear of disappointing a partner;
  • previous negative sexual experiences;
  • guilt or shame surrounding sexuality;
  • cultural or religious beliefs;
  • previous sexual trauma; and
  • excessive focus on whether orgasm is going to occur.

Importantly, identifying a psychological contribution does not mean that the symptoms are imaginary.

Psychological factors cause genuine changes in arousal, attention, autonomic nervous system activity and sexual response.


How Can Anorgasmia Affect a Relationship?

The effects can extend well beyond the bedroom.

The person experiencing anorgasmia may feel:

  • frustrated;
  • embarrassed;
  • inadequate;
  • anxious;
  • less interested in initiating sex; or
  • concerned that something is physically wrong.

Their partner may interpret the problem quite differently:

“Am I no longer attractive?”

“Am I doing something wrong?”

“Why can’t I satisfy my partner?”

Neither interpretation may be correct.

When couples stop talking about the problem, however, assumptions quickly fill the silence. ISSM notes that orgasmic disorders can cause distress for both individuals and their partners.

Open communication can therefore be an important part of treatment.


How Is Anorgasmia Investigated?

There is no single “anorgasmia test.”

Assessment usually begins with a careful and confidential discussion.

Your doctor may ask:

  • Have you ever experienced orgasm?
  • Did the problem start suddenly or gradually?
  • Can you orgasm during masturbation?
  • Can you orgasm with a partner?
  • Are erections normal?
  • Has genital sensation changed?
  • Is sexual desire normal?
  • Have you started any new medications?
  • Have you had pelvic or prostate surgery?
  • Are there neurological symptoms?
  • Is ejaculation occurring normally?
  • Are there significant stresses or relationship difficulties?

Depending upon the circumstances, further assessment may include a physical examination, neurological assessment, medication review and selected blood tests.

Testing is guided by the history rather than performing an enormous battery of investigations for everyone.


Treatment

Treatment should be directed toward the underlying cause wherever possible.

Review medications

If symptoms began after starting an antidepressant or another medication, discuss this with the prescribing doctor.

Options may sometimes include:

  • dose adjustment;
  • changing medication;
  • changing timing; or
  • considering an alternative treatment.

This must be done under medical supervision.


Treat associated erectile dysfunction

If erections are unreliable, optimising erectile function may improve stimulation and the likelihood of orgasm.


Address hormonal abnormalities

Documented testosterone deficiency or other hormonal abnormalities should be treated appropriately rather than assuming that testosterone will improve orgasm in everyone.


Modify stimulation

Changing the type and intensity of sexual stimulation can be remarkably useful for some people.

This might involve:

  • longer periods of stimulation;
  • changing masturbation technique;
  • varying pressure and speed;
  • incorporating different forms of stimulation;
  • reducing dependence on one very specific masturbation technique; and
  • communicating more clearly with a partner about what actually feels pleasurable.

For women, directed self-stimulation, education about sexual anatomy and appropriate clitoral stimulation are established components of management.


Sex Therapy and Psychological Treatment

A psychologist or appropriately trained psychosexual therapist can be extremely valuable.

Therapy is not simply sitting on a couch discussing childhood while everyone carefully avoids mentioning sex.

Modern psychosexual therapy can be practical and goal-directed.

Treatment may include:

  • reducing performance anxiety;
  • cognitive behavioural therapy;
  • mindfulness techniques;
  • sensate-focus exercises;
  • addressing negative beliefs surrounding sex;
  • working through previous traumatic experiences;
  • improving communication;
  • changing established patterns of sexual stimulation; and
  • couples therapy.

Mindfulness can be particularly helpful in shifting attention away from:

“Am I going to orgasm?”

and back towards:

“What am I actually feeling?”

Psychotherapy, cognitive behavioural approaches, mindfulness-based therapy and sex therapy all have roles in selected patients with orgasmic disorders.

Sometimes removing orgasm as the immediate “goal” of sexual activity paradoxically makes orgasm easier to achieve.


Are There Medications for Anorgasmia?

This is an evolving area.

Various medications have been investigated for male delayed orgasm or anorgasmia, but evidence remains limited and there is currently no universally effective medication specifically approved to restore orgasm.

For women with orgasmic disorder, there is likewise no established medication that reliably restores orgasm.

Treatment therefore needs to be individualised.

Beware of internet advertisements promising tablets or supplements that “guarantee” orgasm. Sexual neurophysiology is considerably more complicated than the advertising department would have you believe.


What About Orgasm Without Pleasure?

Occasionally a person experiences the physical event of orgasm or ejaculation but feels little or no pleasure.

This is sometimes described as orgasmic anhedonia or pleasure-dissociative orgasmic dysfunction.

Potential contributors include medications, psychological factors, hormonal abnormalities and neurological problems. Assessment should again concentrate on identifying and treating the underlying cause.


Is There Hope?

Yes.

Anorgasmia can be persistent, but it should not automatically be regarded as permanent.

The first objective is to establish why orgasm has become difficult.

Sometimes the answer is relatively straightforward: a medication, erectile dysfunction, inadequate stimulation or a hormonal problem.

Sometimes several factors are interacting.

And sometimes the physical problem creates anxiety, which then perpetuates the physical problem.

Successful treatment may therefore require more than one approach:

medical assessment + medication review + optimisation of sexual function + appropriate stimulation + psychological or psychosexual therapy.

The AUA specifically recognises education and psychological-health expertise as important components in caring for men with delayed ejaculation and related orgasmic difficulties.


When Should I See a Urologist?

Consider seeking medical advice when:

  • you previously experienced normal orgasms and suddenly cannot;
  • the problem persists and bothers you;
  • you have reduced genital sensation;
  • you also have erectile dysfunction;
  • symptoms developed following pelvic or prostate surgery;
  • symptoms began after starting medication;
  • ejaculation has disappeared or significantly changed;
  • you have neurological symptoms; or
  • the problem is causing anxiety or relationship difficulties.

There is no reason to be embarrassed about discussing orgasm with your urologist.

Sexual function is part of normal human health, and orgasmic problems are legitimate medical concerns.

The Bottom Line

Anorgasmia is rarely as simple as something being “broken.”

Orgasm sits at the intersection of the brain, nerves, hormones, genital sensation, medications, sexual stimulation, emotions and relationships.

That complexity can make anorgasmia challenging to investigate, but it also creates multiple opportunities for treatment.

The most useful approach is often multidisciplinary, combining medical evaluation with attention to psychological and relationship factors.

Most importantly, don’t quietly give up on your sex life.

Anorgasmia deserves proper assessment, an open conversation and an individualised treatment plan. There may not always be a magic switch, but there are often several switches worth checking.

Premature Ejaculation: When Things Happen Earlier Than You’d Like

Premature ejaculation (PE) is one of the most common sexual concerns affecting men. Yet it is also one of the least discussed.

Many men worry that they are the only person experiencing it, or that it means there is something fundamentally wrong with their sexual function or relationship. Neither is necessarily true.

Premature ejaculation is common, often treatable, and usually manageable. Treatment may involve behavioural techniques, psychological or sex therapy, medication, treatment of an underlying medical problem, or a combination of these approaches.

What Is Premature Ejaculation?

There is no stopwatch that defines a satisfying sex life.

Premature ejaculation is better understood as ejaculation that repeatedly occurs sooner than a man or couple would like, with difficulty delaying ejaculation and resulting frustration, distress, avoidance of sexual activity or relationship difficulties.

In lifelong PE, ejaculation often occurs within approximately one minute of vaginal penetration, although the definition is not simply about time. In acquired PE, there is usually a noticeable and troublesome reduction in the time to ejaculation compared with the man’s previous experience.

Importantly, occasional rapid ejaculation is normal and does not necessarily mean that you have PE.

The key questions are:

  • Does it happen repeatedly?
  • Do you feel unable to control or delay ejaculation?
  • Is it causing distress for you or your partner?
  • Has something changed from how things used to be?

If the answer to several of these questions is yes, it may be worth discussing with your GP or urologist.

The Two Main Types of Premature Ejaculation

Lifelong Premature Ejaculation

Lifelong, or primary, PE usually begins with a man’s earliest sexual experiences and continues throughout adult life.

Ejaculation typically occurs very quickly during most sexual encounters and there may be very little sense of control over when ejaculation occurs.

There appears to be an important biological component to lifelong PE. Differences in serotonin signalling and individual sensitivity of the ejaculatory reflex have been proposed.

In other words, lifelong PE is not simply a matter of poor self-control.

Acquired Premature Ejaculation

Acquired, or secondary, PE develops in a man who previously had satisfactory control over ejaculation.

This distinction is important because acquired PE may have an identifiable contributing factor.

Possible associations include:

  • erectile dysfunction
  • performance anxiety
  • relationship difficulties
  • stress or depression
  • prostatitis or pelvic discomfort in some men
  • thyroid disorders, particularly hyperthyroidism
  • changes in medications or recreational drug use
  • changes in sexual circumstances
  • prolonged periods without sexual activity

When PE develops relatively suddenly, identifying and treating the underlying problem may substantially improve ejaculation.

What Causes Premature Ejaculation?

There is rarely one simple explanation.

Ejaculation is controlled through a complex interaction between the brain, spinal cord, peripheral nerves, hormones, neurotransmitters, sexual stimulation and psychological factors.

Biological Factors

Serotonin is particularly important in controlling ejaculation. Certain serotonin pathways appear to delay ejaculation, which helps explain why medications that increase serotonin activity can be effective treatments for PE.

Genetic and neurobiological differences may therefore explain why some men naturally have a much shorter ejaculatory latency than others.

Erectile Dysfunction

This is an important and sometimes overlooked relationship.

A man who is worried about losing his erection may unconsciously hurry sexual activity and ejaculation. This can gradually create a pattern of rapid ejaculation.

Treating the erectile dysfunction can sometimes significantly improve the PE as well.

Is Premature Ejaculation “All in the Mind”?

No.

But psychology can certainly play a role.

This distinction is important.

Premature ejaculation can have genuine biological components, particularly in lifelong PE. Telling a man simply to “relax” is therefore unlikely to solve the problem.

At the same time, anxiety can amplify the problem.

A common cycle develops:

Rapid ejaculation → worry about the next sexual encounter → increased monitoring and performance anxiety → increased arousal → even faster ejaculation.

Sex can gradually begin to feel more like an examination than something enjoyable.

Breaking this cycle can be an important part of treatment.

The Role of Psychology and Sex Therapy

Psychological therapy can be particularly helpful when PE is associated with:

  • performance anxiety
  • relationship tension
  • fear of sexual failure
  • depression or general anxiety
  • unrealistic expectations about sexual performance
  • avoidance of intimacy
  • reduced sexual confidence

Psychosexual counselling can also help couples communicate more openly about sexual expectations.

For some men, combining psychological or behavioural therapy with medication is more effective than relying on either approach alone.

The aim is not to suggest that PE is imaginary. Rather, treatment addresses both the physical ejaculatory reflex and the psychological environment surrounding it.

Behavioural Techniques

Several techniques can help some men develop greater awareness and control of their level of sexual arousal.

Stop-Start Technique

Sexual stimulation is stopped when ejaculation feels close. Once the sensation subsides, stimulation begins again.

With practice, this may help a man recognise the point at which ejaculation becomes difficult to stop.

Squeeze Technique

A variation involves briefly stopping stimulation and applying gentle pressure to the penis when ejaculation feels imminent.

This technique is used less commonly today but can still be useful for some couples.

Pelvic Floor Training

The pelvic floor muscles are involved in ejaculation as well as urinary control.

Some men may benefit from learning better awareness and control of these muscles, particularly under the guidance of a pelvic floor physiotherapist with experience in male sexual dysfunction.

More exercise is not necessarily better. Excessive pelvic floor tension may actually be counterproductive in some men.

Condoms and Reduced Sensitivity

Condoms reduce penile sensation and may delay ejaculation in some men.

Thicker condoms or condoms specifically designed to reduce sensitivity may provide additional benefit.

This is a simple and low-risk option worth trying before progressing to medication.

Local Anaesthetic Creams and Sprays

Topical anaesthetic preparations containing agents such as lidocaine and/or prilocaine can reduce penile sensitivity and delay ejaculation.

They are generally applied before sexual activity.

Potential problems include:

  • excessive penile numbness
  • reduced sexual pleasure
  • irritation
  • transfer of the anaesthetic to a partner, causing genital numbness

Using the correct amount and following product instructions is important. A condom may sometimes help prevent transfer to a partner.

Medication for Premature Ejaculation

Several medications can delay ejaculation.

SSRIs

Selective serotonin reuptake inhibitors, or SSRIs, were originally developed as antidepressants. One of their recognised effects is delayed ejaculation.

Medications such as paroxetine, sertraline, fluoxetine and escitalopram may therefore sometimes be prescribed for PE.

Depending on the medication and clinical circumstances, treatment may be taken daily rather than immediately before sexual activity.

Possible side effects include:

  • nausea
  • tiredness
  • sweating
  • reduced libido
  • erectile difficulties
  • changes in mood
  • difficulty reaching orgasm

These medications should be prescribed and monitored by an appropriate medical practitioner and should not be started, stopped or altered without medical advice.

Dapoxetine

Dapoxetine is a short-acting SSRI specifically developed for premature ejaculation and is taken before anticipated sexual activity rather than continuously.

Its availability and regulatory status vary between countries, including Australia, so treatment needs to be discussed with your doctor rather than purchased from unregulated online sources.

PDE5 Inhibitors

Medications such as sildenafil or tadalafil primarily treat erectile dysfunction rather than PE.

They may nevertheless be helpful when premature ejaculation occurs together with erectile dysfunction.

For some men, improving confidence in the reliability of their erection also reduces the urge to rush sexual activity.

What About Tramadol?

Tramadol can delay ejaculation, but it is an opioid medication and carries risks including sedation, dependence, interactions with other medications and other potentially serious adverse effects.

For these reasons, it is not usually considered a preferred first-line treatment for PE.

Is Testosterone Treatment Helpful?

Usually not.

Testosterone replacement is not a routine treatment for premature ejaculation.

If symptoms or examination suggest testosterone deficiency or another hormonal problem, appropriate blood tests may be performed. Hormone treatment should only be considered when a genuine hormonal abnormality has been demonstrated.

Is Surgery the Answer?

Generally, no.

Premature ejaculation is not normally treated surgically.

Procedures designed to permanently reduce penile sensation or alter penile nerves are controversial and can potentially cause permanent numbness, altered sensation, pain or sexual dysfunction.

Treatment should usually begin with reversible, evidence-based approaches.

When Should You See a Urologist?

Consider seeking medical advice when PE:

  • occurs during most sexual encounters
  • is causing significant distress
  • is affecting your relationship
  • has developed suddenly
  • occurs together with erectile dysfunction
  • is associated with urinary symptoms, pelvic pain or penile discomfort
  • has not responded to simple measures

A consultation does not necessarily mean extensive testing.

For many men, the most useful part of the assessment is simply a careful conversation about when the problem began, erectile function, sexual circumstances, medications, general health and any associated urinary or hormonal symptoms.

Blood tests or other investigations may occasionally be appropriate depending on the circumstances.

Is There Hope?

Absolutely.

Premature ejaculation is not a measure of masculinity, fertility or the quality of a relationship.

It is a common sexual dysfunction with several potential treatment strategies. Some men respond well to relatively simple measures. Others benefit from medication, treatment of associated erectile dysfunction, psychosexual therapy, or a combination of approaches.

Perhaps most importantly, treatment should not focus exclusively on adding minutes to a stopwatch.

The real goals are better control, less anxiety, greater sexual confidence and a more satisfying sexual experience for both partners.

There is no universally “correct” duration for sex.

If ejaculation is consistently occurring earlier than you would like and it is bothering you, that is reason enough to discuss it.

A Final Word

Premature ejaculation can be difficult to bring up in conversation, but for a urologist it is an everyday medical issue.

You will almost certainly not be the first person to mention it that day.

And occasionally, the most effective first treatment is simply getting the subject out of the bedroom shadows and into a conversation where something can actually be done about it.

This information is intended for general patient education and does not replace individual medical assessment. Treatment should be tailored to your medical history, medications, symptoms and circumstances.

Robotic-Assisted Radical Prostatectomy: When Is a Non-Nerve-Sparing Procedure Necessary?

Removing the prostate while putting cancer control first

Robotic-assisted radical prostatectomy is a well-established surgical treatment for localised and selected locally advanced prostate cancer. During the operation, the prostate gland and seminal vesicles are removed, and the bladder is reconnected to the urethra. In selected patients, pelvic lymph nodes may also be removed.

One of the important decisions made before and during prostate cancer surgery is whether the nerves responsible for erections can safely be preserved.

This is known as nerve-sparing prostatectomy.

Unfortunately, nerve preservation is not always appropriate. When prostate cancer is close to, involves, or is suspected of extending beyond the outer edge of the prostate near these nerves, attempting to preserve them may compromise the completeness of cancer removal.

In this situation, a partial or complete non-nerve-sparing robotic prostatectomy may be recommended.

The guiding principle is simple:

Preserve the nerves when it is oncologically safe to do so, but do not preserve them at the expense of adequately treating the prostate cancer.


What are the nerves that are being “spared”?

Running immediately alongside the prostate are delicate bundles of nerves and blood vessels known collectively as the neurovascular bundles.

These structures contain nerves that play an important role in producing erections.

They sit extremely close to the outer surface, or capsule, of the prostate. This anatomical relationship creates a challenge during prostate cancer surgery.

If the cancer is safely contained within the prostate and sufficiently distant from the neurovascular bundle, the surgeon may be able to carefully dissect the prostate away while preserving the nerves.

This is a nerve-sparing radical prostatectomy.

If cancer is suspected to extend towards or through the prostate capsule in this area, the surgeon may need to remove some or all of the neurovascular tissue together with the prostate.

This is a non-nerve-sparing prostatectomy.


Why would a surgeon deliberately remove the erectile nerves?

It may initially seem counterintuitive to remove structures that are so important for sexual function.

The reason is cancer control.

The primary purpose of radical prostatectomy is to completely remove the prostate cancer.

If a tumour is growing very close to the edge of the prostate, particularly next to a neurovascular bundle, dissecting too close to the prostate in an attempt to preserve the nerves could potentially leave cancer cells behind.

This is called a positive surgical margin.

In appropriately selected patients, taking a wider margin around the prostate may therefore provide a safer cancer operation.

The decision represents a balance between:

Cancer control

and

preservation of erectile function.

When these two goals conflict, cancer control generally takes priority.


When may a non-nerve-sparing prostatectomy be recommended?

Non-nerve-sparing surgery may be considered when there is a significant risk that prostate cancer has extended towards or into the tissues surrounding the prostate.

Examples include:

Locally advanced prostate cancer

A tumour suspected of extending through the prostate capsule, particularly clinical T3 disease, may require a wider surgical excision.

Cancer close to the neurovascular bundle on MRI

Modern multiparametric prostate MRI can provide valuable information about the location of the tumour and its relationship to the prostate capsule and neurovascular bundles.

Features suggesting extraprostatic extension may influence the decision not to preserve the nerve bundle on that side.

High-grade prostate cancer

Higher-grade cancers, including cancers with an unfavourable Gleason score or ISUP Grade Group, may have a greater likelihood of extending outside the prostate.

The biopsy result alone does not automatically determine whether the nerves can be preserved, but it forms part of the overall assessment.

Extensive cancer on prostate biopsy

Large-volume disease, particularly when concentrated along the outer portion of the prostate near a neurovascular bundle, may make nerve preservation less appropriate.

Very high PSA or other high-risk features

PSA level, PSA density, biopsy findings, MRI appearance and clinical examination are considered together when estimating the likelihood of disease extending beyond the prostate.

Cancer involving one particular side of the prostate

Importantly, nerve sparing does not necessarily have to be “all or nothing.”

If the cancer is predominantly on one side, it may sometimes be possible to preserve the neurovascular bundle on the opposite side.

This is known as unilateral nerve sparing.


Nerve sparing is not simply YES or NO

Modern robotic prostate surgery is more nuanced than dividing operations into completely nerve-sparing and completely non-nerve-sparing procedures.

Depending on the location and extent of the cancer, surgery may involve:

  • Bilateral nerve sparing
  • Unilateral nerve sparing
  • Partial nerve sparing
  • Wider excision on one side and nerve preservation on the other
  • Complete bilateral non-nerve-sparing surgery

The surgical plan can therefore be tailored to the individual patient and, importantly, to the cancer on each side of the prostate.


How does nerve-sparing surgery differ from non-nerve-sparing surgery?

During nerve-sparing surgery, the surgeon carefully separates the neurovascular bundle from the surface of the prostate while attempting to minimise traction, heat and other potential injury to these delicate nerves.

During non-nerve-sparing surgery, the dissection is deliberately performed further away from the prostate.

The neurovascular tissue is removed together with the prostate where necessary to obtain a wider cancer margin.

The robotic platform provides magnified three-dimensional vision and highly controlled instrument movement. This allows the surgeon to identify tissue planes with considerable precision.

However, robotic technology cannot make an unsafe nerve-sparing operation safe.

The biology and location of the cancer ultimately determine how close to the prostate the surgeon can safely operate.


What happens to erections after non-nerve-sparing prostatectomy?

This is one of the most important issues to discuss before surgery.

The nerves surrounding the prostate are responsible for signalling increased blood flow into the penis to produce a natural erection.

If both neurovascular bundles are completely removed, the likelihood of recovering spontaneous erections adequate for sexual intercourse is very low.

This is different from nerve-sparing surgery, where the nerves remain anatomically intact but may temporarily function poorly following surgery.

After nerve-sparing prostatectomy, erectile recovery can occur gradually over many months and sometimes over 18–24 months or longer.

After complete bilateral non-nerve-sparing surgery, however, the nerves themselves have been removed rather than temporarily stunned.

The expectations for recovery are therefore very different.


Does non-nerve-sparing surgery affect sensation or orgasm?

This is an important distinction.

The nerves responsible for penile sensation are different from the neurovascular nerves primarily responsible for erections.

Many men can therefore continue to experience penile sensation and sexual pleasure following radical prostatectomy.

Orgasm may also remain possible.

However, radical prostatectomy removes the prostate and seminal vesicles and disconnects the reproductive pathway. Consequently, there is no ejaculation of semen after surgery.

This is sometimes described as a dry orgasm.

The sensation of orgasm can also feel different after prostate surgery.


Does non-nerve-sparing prostatectomy cause infertility?

Yes.

Radical prostatectomy results in permanent infertility because the prostate and seminal vesicles are removed and sperm can no longer enter the ejaculate.

Men who may wish to father children in the future should discuss sperm banking before surgery.

This applies whether the operation is nerve sparing or non-nerve sparing.


Is a non-nerve-sparing procedure reversible?

No.

Once a neurovascular bundle has been surgically removed, it cannot simply be reattached at a later date.

This is an important difference between temporary nerve dysfunction and actual nerve removal.

After nerve-sparing surgery, the nerves may be anatomically preserved but temporarily injured or “stunned”. Recovery may therefore occur with time.

After complete non-nerve-sparing surgery, the erectile nerves have been physically removed as part of the cancer operation.

The procedure itself is therefore not reversible.

However, this does not mean that erections or sexual activity are impossible.

There are several effective treatments available for erectile dysfunction following prostatectomy.


Can erections still be achieved after non-nerve-sparing surgery?

Rarely yes, but they will usually require assistance.

Treatment options include:

PDE5 inhibitor tablets

Medications such as sildenafil or tadalafil are commonly used after prostate surgery.

They rely substantially on functioning nerve pathways and are therefore generally more effective following nerve-sparing surgery.

Their effectiveness following complete bilateral non-nerve-sparing surgery is considerably more limited.

Vacuum erection device

A vacuum erection device creates negative pressure around the penis, drawing blood into the erectile tissues.

A constriction ring can then be placed around the base of the penis to maintain the erection.

Because this technique does not depend on intact erectile nerves, it can be useful after non-nerve-sparing surgery.

Penile injection therapy

Medication can be injected directly into the erectile tissue of the penis.

These medications act directly on penile blood vessels and therefore do not require normal prostate-associated nerve signalling.

For this reason, penile injections can be highly effective even after bilateral non-nerve-sparing prostatectomy.

Penile prosthesis

For men with persistent erectile dysfunction who wish to restore reliable erections, a penile prosthesis can provide an effective long-term solution.

An inflatable penile prosthesis allows an erection to be mechanically produced when desired.

For appropriately selected men, satisfaction rates following penile prosthesis surgery are generally high.


What about penile rehabilitation?

Penile rehabilitation may be discussed following radical prostatectomy.

The objectives can include maintaining penile tissue health, encouraging regular oxygenation of the erectile tissues, minimising shortening and fibrosis, and assisting the return to sexual activity.

A rehabilitation program may involve:

  • PDE5 inhibitor medication where appropriate
  • Vacuum erection therapy
  • Penile injection therapy
  • Regular sexual stimulation
  • Early assessment and management of erectile dysfunction

The appropriate program depends heavily on whether surgery was bilateral nerve sparing, unilateral nerve sparing or completely non-nerve sparing.

It is therefore important that expectations are realistic.

After complete bilateral nerve removal, rehabilitation cannot make the removed nerves grow back. Instead, treatment focuses on maintaining penile health and providing alternative ways of achieving an erection.


Can the surgeon decide during the operation whether to spare the nerves?

Sometimes.

The intended degree of nerve sparing is usually planned before surgery using information from:

  • Prostate MRI
  • Prostate biopsy
  • PSA
  • Clinical examination
  • Location and volume of cancer
  • Gleason score and ISUP Grade Group
  • Estimated risk of extraprostatic extension
  • The patient’s existing erectile function
  • The patient’s priorities regarding cancer control and sexual function

However, the final surgical approach may occasionally need to be modified according to findings encountered during the operation.

The most important objective remains adequate removal of the cancer.


Does non-nerve-sparing surgery improve cancer cure rates?

Not every patient benefits from wider surgery.

For men with cancer safely confined within the prostate, unnecessary removal of the neurovascular bundles may produce significant functional consequences without providing additional cancer benefit.

Conversely, when cancer is suspected of extending close to or beyond the prostate capsule adjacent to a neurovascular bundle, wider excision may reduce the risk of leaving tumour at the surgical margin.

This is why the decision must be individualised.

The best operation is not automatically the operation that preserves the most nerves. It is the operation that provides appropriate cancer clearance while preserving as much normal function as can safely be preserved.


What about urinary continence?

Nerve sparing primarily relates to erectile function, rather than the urinary sphincter responsible for continence.

Urinary control after radical prostatectomy depends on several factors including:

  • Age
  • Pre-operative urinary function
  • Pelvic floor strength
  • Urethral length
  • Bladder function
  • Surgical anatomy and technique
  • Previous prostate treatments
  • Individual healing

Pelvic floor rehabilitation before and after surgery can be an important part of recovery.

Non-nerve-sparing surgery does not automatically mean that a patient will remain incontinent.


Questions worth asking before surgery

If a non-nerve-sparing robotic prostatectomy has been recommended, useful questions to discuss with your urologist include:

Why is nerve preservation considered unsafe in my particular cancer?

Is the concern on one side or both sides of the prostate?

Could unilateral or partial nerve sparing be considered?

What does my MRI show about the relationship between the cancer and neurovascular bundles?

What is my estimated chance of erectile recovery with the proposed operation?

What erectile rehabilitation options will be available after surgery?

Should I consider sperm banking before treatment?

These conversations are particularly important because the decision to remove a neurovascular bundle is generally irreversible.


The important message

A non-nerve-sparing robotic-assisted radical prostatectomy is not an inferior version of nerve-sparing surgery.

In the right patient, it is a deliberate cancer-control strategy.

When prostate cancer is close to or suspected of involving the tissues surrounding the prostate, preserving the erectile nerves too aggressively may risk leaving cancer behind.

Modern robotic surgery allows the operation to be tailored to the individual patient. Some men can undergo bilateral nerve preservation, others may benefit from preservation on only one side, while patients with more extensive disease may require a wider non-nerve-sparing excision.

The consequences for erectile function are important and should be understood before surgery.

Once the neurovascular nerves have been removed, the procedure cannot be reversed.

However, loss of spontaneous erections does not mean the end of sexual intimacy. Vacuum devices, penile injection therapy and penile prostheses can provide effective options when natural erections are no longer possible.

Ultimately, the aim is to achieve the best possible balance between two important goals:

Effective treatment of the prostate cancer and preservation of quality of life.


A note for patients

Every prostate cancer is different. MRI findings, biopsy results, PSA, cancer grade, age, general health, pre-existing erectile function and personal priorities all influence the appropriate surgical approach.

A detailed discussion with your urologist before robotic prostatectomy is essential so that you understand whether nerve sparing is appropriate, what degree of nerve preservation may be possible and what this means for cancer control, continence and sexual function.

This information is intended for general patient education and does not replace individual medical advice. Treatment recommendations should be based on your individual prostate cancer characteristics, imaging, pathology, general health and discussion with your treating urologist.

So., come chat to your Brisbane based urologist, Jo to discuss this option with you.

Medications for Overactive Bladder in Australia: What Are the Options?

Overactive bladder (OAB) can make life feel as though the bladder has taken control of the daily timetable. A trip to the shops becomes a mental map of toilets, a long car journey requires strategic planning, and the sound of running water can suddenly become surprisingly persuasive.

Fortunately, several medications are available in Australia that can reduce urinary urgency, frequency and urgency urinary incontinence.

What is an overactive bladder?

Overactive bladder is a symptom syndrome characterised by urinary urgency, usually accompanied by increased urinary frequency and nocturia, with or without urgency urinary incontinence.

Typical symptoms include:

  • A sudden compelling need to urinate that is difficult to postpone
  • Passing urine frequently during the day
  • Waking repeatedly at night to urinate
  • Leakage of urine before reaching the toilet
  • Having to plan activities around access to toilets

Importantly, OAB is a clinical diagnosis rather than simply a finding on urodynamic testing. Some patients with OAB demonstrate detrusor overactivity during urodynamic studies, while others do not.

Before starting medication, potentially reversible causes should be considered, including urinary tract infection, excessive fluid or caffeine intake, poorly controlled diabetes, constipation, bladder stones and bladder outlet obstruction.

In men, particularly those with prostate enlargement, it is important to determine whether urgency is occurring together with significant bladder outlet obstruction and incomplete bladder emptying.


When should medication be considered?

Initial management will often include conservative measures such as:

  • Bladder training
  • Timed voiding
  • Reduction of excessive caffeine
  • Modification of excessive fluid intake
  • Weight reduction where appropriate
  • Treatment of constipation
  • Pelvic floor physiotherapy
  • Management of contributing vaginal or genitourinary changes associated with menopause

Medication may be offered when symptoms remain bothersome despite conservative measures, or when the severity of symptoms warrants combining behavioural and pharmacological treatment.

The two major medication groups used for OAB are:

  1. Antimuscarinic or anticholinergic medications
  2. Beta-3 adrenergic agonists, principally mirabegron

Australian guidance notes broadly similar efficacy between beta-3 agonist and anticholinergic therapy, although their adverse-effect profiles are quite different.


1. Oxybutynin

Oxybutynin is one of the longest-established medications for overactive bladder and detrusor overactivity.

In Australia it is available in oral formulations, and transdermal oxybutynin patches are also available. Current PBS listings include oxybutynin 5 mg tablets and a 3.9 mg/24-hour transdermal patch.

How does it work?

Oxybutynin blocks muscarinic receptors involved in detrusor contraction. This reduces involuntary bladder contractions and can improve urgency, frequency and urgency incontinence.

Advantages

Oxybutynin is well established, effective in appropriately selected patients and relatively inexpensive.

The transdermal patch may produce fewer systemic anticholinergic effects, particularly dry mouth, than conventional oral treatment.

Common side effects

These include:

  • Dry mouth
  • Constipation
  • Dry eyes
  • Blurred vision
  • Drowsiness
  • Dizziness
  • Difficulty emptying the bladder
  • Cognitive disturbance, particularly in older patients

Oxybutynin can cross the blood-brain barrier, making cognitive adverse effects an important consideration, especially in elderly or vulnerable patients.

When should oxybutynin be avoided or used cautiously?

Particular caution is required in patients with:

  • Significant urinary retention
  • Gastric retention or severe gastrointestinal motility disorders
  • Uncontrolled narrow-angle glaucoma
  • Myasthenia gravis
  • Significant constipation
  • Cognitive impairment
  • A high existing anticholinergic medication burden

2. Solifenacin

Solifenacin is another antimuscarinic medication widely used for OAB.

The TGA indication includes treatment of overactive bladder associated with urgency urinary incontinence, urgency or increased urinary frequency.

It is commonly prescribed once daily.

Advantages

Solifenacin is relatively bladder-selective and once-daily dosing is convenient. Many patients tolerate it better than immediate-release oxybutynin.

Common side effects

These include:

  • Dry mouth
  • Constipation
  • Blurred vision
  • Dry eyes
  • Dyspepsia
  • Difficulty passing urine
  • Urinary retention

Higher doses may improve symptoms in some patients but generally increase anticholinergic adverse effects.

Contraindications and precautions

Solifenacin should be avoided or used cautiously in patients with significant urinary retention, severe gastrointestinal retention, uncontrolled narrow-angle glaucoma and certain significant cardiac rhythm abnormalities.

Renal and hepatic impairment and potential drug interactions should also be considered when selecting the dose.


3. Other antimuscarinic medications

Other antimuscarinic agents that may be encountered in the management of OAB include drugs such as darifenacin, tolterodine and fesoterodine, depending on current Australian availability, registration, individual circumstances and prescribing arrangements.

Although the individual pharmacology varies, their overall therapeutic principle is similar: reducing muscarinic stimulation of the bladder.

The familiar anticholinergic family of adverse effects therefore remains:

dry mouth + constipation + blurred vision + possible urinary retention.

There is no perfect “bladder-only” anticholinergic medication. Muscarinic receptors are distributed throughout the body, which explains why medications intended to calm the bladder may simultaneously make the mouth dry and the bowel somewhat less enthusiastic.


Anticholinergic medications and memory

This deserves particular attention.

Increasing evidence has raised concern about the cumulative anticholinergic burden, especially in older people.

Anticholinergic medications can contribute to:

  • Confusion
  • Sedation
  • Cognitive impairment
  • Falls
  • Functional decline

Long-term exposure to medications with strong anticholinergic activity has also been associated in observational research with cognitive decline and dementia, although an association does not by itself prove that an individual OAB medication causes dementia.

Australian Prescriber specifically highlights that cumulative exposure to drugs with anticholinergic effects may contribute to cognitive decline and loss of functional capacity in older people.

For this reason, medication selection should consider the patient’s total anticholinergic burden, including medications prescribed for depression, allergies, sleep disorders and other conditions.

In an older patient, particularly one with existing cognitive concerns, a beta-3 agonist may therefore be preferable when clinically appropriate. Recent Australian Therapeutic Guidelines discussion similarly recommends particular caution with conventional anticholinergic therapy in patients over 65 years.


4. Mirabegron

Mirabegron is a beta-3 adrenergic receptor agonist and provides an important alternative to anticholinergic therapy.

Rather than blocking acetylcholine, mirabegron stimulates beta-3 receptors in the bladder detrusor, promoting relaxation during bladder filling and thereby increasing functional bladder storage.

It is TGA-approved for overactive bladder.

Who may benefit from mirabegron?

It can be particularly useful in patients who:

  • Cannot tolerate anticholinergic medications
  • Develop troublesome dry mouth or constipation
  • Have concerns regarding cognitive adverse effects
  • Have an already high anticholinergic medication burden
  • Have had an inadequate response to an antimuscarinic

Advantages

Mirabegron causes substantially fewer classic anticholinergic adverse effects such as dry mouth and constipation.

Its efficacy is broadly comparable with anticholinergic therapy, making tolerability an important part of choosing between the two classes.

Side effects

Potential adverse effects include:

  • Increased blood pressure
  • Headache
  • Palpitations
  • Tachycardia
  • Urinary tract infection
  • Occasionally urinary retention

Atrial fibrillation has also been reported.

Hypertension is important

Blood pressure should be assessed when considering mirabegron.

It should be avoided in patients with severe or poorly controlled hypertension, and blood pressure monitoring is advisable during treatment. Australian guidance highlights particular concern around blood pressure of approximately 180/110 mmHg or greater.

Drug interactions

Mirabegron inhibits the CYP2D6 enzyme, meaning it can increase exposure to certain medications metabolised through this pathway.

Extra care may therefore be necessary with drugs such as some beta blockers, antidepressants and anti-arrhythmic medications. Particular caution is appropriate with narrow-therapeutic-index CYP2D6 substrates such as flecainide and propafenone.


Can medications be combined?

Yes.

For patients who experience a partial response to a single medication, combination therapy using a beta-3 agonist plus an antimuscarinic may sometimes provide additional symptom improvement.

However, combination treatment may also increase adverse effects and requires careful patient selection.

In men with coexisting benign prostate enlargement and bladder outlet symptoms, an OAB medication may sometimes be combined with an alpha blocker, particularly when storage symptoms such as urgency and frequency remain troublesome after treatment of the obstructive component.

A post-void residual urine measurement can be particularly useful before escalating treatment in patients at risk of incomplete bladder emptying.


What about vaginal oestrogen?

Postmenopausal women with OAB may also have symptoms of genitourinary syndrome of menopause, including vaginal dryness, irritation, recurrent urinary infections and urinary urgency.

Where vaginal atrophy is present, local vaginal oestrogen may form part of management rather than simply escalating conventional OAB medication. This approach is also recognised in contemporary Australian guidance.


Which OAB medication is best?

There is no single winner.

Treatment should be individualised according to:

Clinical situation Medication consideration
Younger patient without major comorbidity Antimuscarinic or mirabegron
Significant dry mouth Consider mirabegron
Severe constipation Avoid or minimise anticholinergic therapy
Older patient/cognitive concerns Minimise anticholinergic burden
Significant uncontrolled hypertension Avoid mirabegron
Poor bladder emptying/high residual urine Use OAB medication cautiously
Narrow-angle glaucoma Antimuscarinics may be inappropriate
Partial response to one drug Consider dose adjustment, alternative agent or combination therapy
OAB with vaginal atrophy Consider local vaginal oestrogen as part of treatment
OAB with male bladder outlet obstruction Assess obstruction and residual urine before escalating therapy

How long should medication be tried?

OAB medications do not work instantly.

Patients will generally require a therapeutic trial followed by reassessment of:

  • Urinary frequency
  • Number of urgency episodes
  • Urgency urinary incontinence
  • Nocturia
  • Pad usage
  • Side effects
  • Quality of life

A bladder diary can be particularly useful because it turns a vague impression of improvement into something measurable.

If medication is ineffective, increasing the dose indefinitely is not necessarily the answer. The diagnosis should be reconsidered and other treatment options discussed.


What if tablets do not work?

Medication is only one rung on the OAB treatment ladder.

For patients with persistent, troublesome symptoms despite behavioural therapy and appropriate medication, further investigation may include:

  • Bladder ultrasound and post-void residual measurement
  • Cystoscopy in selected patients
  • Urodynamic studies where the diagnosis or underlying bladder dysfunction requires clarification

More advanced treatment options can include:

Intravesical Botulinum Toxin (Botox)

Botulinum toxin can be injected into the bladder wall to reduce involuntary detrusor activity. It can be highly effective, although urinary tract infection and temporary difficulty emptying the bladder are recognised risks.

Sacral neuromodulation

Sacral neuromodulation uses electrical stimulation of the sacral nerves involved in bladder control and can be considered in appropriately selected patients with refractory OAB.

Other neuromodulation techniques

Posterior tibial nerve stimulation and related neuromodulation approaches may also have a role in selected patients.


The bottom line

Overactive bladder is common, treatable and often requires a stepwise approach rather than simply prescribing a tablet.

Antimuscarinic medications such as oxybutynin and solifenacin remain useful treatments, but their potential for dry mouth, constipation, urinary retention and cognitive adverse effects needs to be considered.

Mirabegron provides an important alternative, particularly when anticholinergic adverse effects are problematic, but blood pressure and potential drug interactions require attention.

The best treatment depends on the individual patient’s symptoms, age, bladder emptying, medical conditions and other medications.

And if tablets fail, that does not mean treatment has reached the end of the road. Botox, neuromodulation and other therapies provide additional options for the bladder that remains stubbornly determined to run its own timetable.

References

  1. Australian Prescriber. Management of urinary incontinence in adults.
  2. Australian Prescriber. Anticholinergic drugs for overactive bladder.
  3. Australian Prescriber. Mirabegron for overactive bladder.
  4. Hilmer SN, Gnjidic D. The anticholinergic burden: from research to practice. Australian Prescriber. 2022;45:118–120.
  5. Therapeutic Goods Administration. Australian Public Assessment Report: Mirabegron.
  6. Therapeutic Goods Administration. Solifenacin registration and approved indication for overactive bladder.
  7. Pharmaceutical Benefits Scheme. Current oxybutynin tablet and transdermal patch listings.
  8. Australian Prescriber. Therapeutic Guidelines Kidney and Urinary, discussion of contemporary OAB pharmacotherapy.

This information is intended for general patient education and does not replace individual medical assessment. Medication availability, PBS eligibility and prescribing restrictions can change. Patients should discuss the most appropriate treatment with their GP, urologist or other treating clinician.

So, if you have overactive bladder symptoms and resonate with this blog, chat to your GP about this and come see me your local Brisbane Urologist, Uro-Jo, if the drugs don’t work.

Regulated Bladder Distension: Can Stretching the Bladder Help a Small or Painful Bladder?

For patients living with interstitial cystitis/bladder pain syndrome (IC/BPS) or a persistently small functional bladder capacity, the bladder can become an unforgiving little alarm clock: filling produces pain or pressure, urinary frequency increases, and sleep may be repeatedly interrupted by trips to the bathroom.

One procedure sometimes considered in carefully selected patients is regulated bladder distension, more commonly called cystoscopic hydrodistension.

Hydrodistension has been used for decades, both to assess the bladder and as a therapeutic procedure. It can improve symptoms in some patients, but it is important to understand that it is not a cure for interstitial cystitis, and the scientific evidence for lasting benefit remains mixed. Current guidelines therefore regard it as a selective treatment rather than something that should routinely be performed in every patient with bladder pain.


What is regulated bladder distension?

Regulated bladder distension involves gradually filling the bladder with sterile irrigation fluid during cystoscopy, usually while the patient is under anaesthesia.

The important word is regulated.

Modern hydrodistension should not simply involve filling the bladder as much as possible. Pressure, volume and duration need to be carefully controlled to minimise injury to the bladder.

A commonly described technique is low-pressure, short-duration hydrodistension, traditionally using an irrigation pressure of approximately 60–80 cm H₂O for less than 10 minutes.

The procedure allows the urologist to:

  • examine the bladder carefully;
  • exclude other abnormalities such as bladder stones or tumours;
  • identify Hunner lesions associated with a particular phenotype of IC/BPS;
  • assess the bladder mucosa following distension;
  • determine the bladder’s anatomical capacity under anaesthesia;
  • identify a severely reduced or fibrotic bladder capacity; and
  • potentially provide temporary improvement in pain, urgency and urinary frequency.

Importantly, the bladder capacity measured under anaesthesia can be very different from the volume a patient can comfortably hold while awake.


Why might bladder distension improve symptoms?

The exact mechanism remains uncertain.

Several explanations have been proposed.

Temporary increase in functional bladder capacity

Some patients with bladder pain develop progressively smaller functional voided volumes because bladder filling produces discomfort or urgency.

Hydrodistension may temporarily allow the bladder to accommodate a larger volume and may interrupt the cycle of:

bladder filling → pain → early voiding → progressively smaller functional capacity.

However, this does not necessarily mean that hydrodistension permanently enlarges a genuinely scarred or fibrotic bladder.

Alteration of bladder sensory signalling

Stretching of the bladder wall may temporarily alter afferent sensory signalling between the bladder and nervous system.

This may reduce the sensation of:

  • urgency;
  • bladder pressure;
  • suprapubic discomfort; and
  • pain associated with bladder filling.

This proposed neuromodulatory effect may explain why some patients experience considerable symptomatic improvement despite relatively little change in anatomical bladder capacity.

Diagnostic and therapeutic treatment of Hunner lesions

Cystoscopy performed during hydrodistension can make Hunner lesions more apparent. Once identified, these lesions can be treated separately with fulguration, laser treatment or steroid injection where appropriate.

It is important to distinguish improvement from treating a Hunner lesion from improvement attributable to the hydrodistension itself.


Hydrodistension for interstitial cystitis/bladder pain syndrome

This is the condition in which hydrodistension has been studied most extensively.

IC/BPS is characterised by bladder-related pain, pressure or discomfort accompanied by urinary symptoms such as frequency and urgency, after other identifiable causes have been excluded.

Hydrodistension is not required to diagnose every patient with IC/BPS, but cystoscopy and distension can be particularly useful when the diagnosis is uncertain, Hunner lesions are suspected, or invasive treatment is being considered.

The European Association of Urology notes that hydrodistension is commonly performed but that the scientific justification remains limited, describing its therapeutic role in primary bladder pain syndrome as limited.

This does not mean that it never works. Rather, we cannot reliably predict who will respond or how long the response will last.


How effective is bladder hydrodistension?

This is where expectations need to be realistic.

Older observational studies of low-pressure, short-duration hydrodistension reported clinically significant improvement in approximately:

Time after treatment Reported symptomatic response
1 month approximately 30–54%
2–3 months approximately 18–56%
5–6 months approximately 0–37%

These studies were generally small and heterogeneous, and many lacked placebo or sham controls.

AUA educational material similarly notes that observational studies have demonstrated meaningful improvement in approximately half of selected patients, sometimes lasting as long as 12 months. The absence of good sham-controlled trials, however, makes the treatment effect difficult to quantify precisely.

The EAU guidelines highlight how quickly benefit can disappear in some patients. In one comparison involving hydrodistension, approximately 70% of patients treated with hydrodistension alone had returned to their previous symptoms after one month.


What does the newer research show?

A recent systematic review provides an important update.

Lim and colleagues reviewed 14 studies involving 1,404 patients undergoing hydrodistension for interstitial cystitis. Nine studies evaluated distension lasting 15 minutes or less, while five older studies investigated considerably longer distension periods.

Some studies demonstrated significant improvements in pain and symptom scores, while others showed no statistically significant improvement.

The authors concluded that hydrodistension can provide symptomatic relief in some patients but that the available evidence remains limited by:

  • heterogeneous techniques;
  • small patient populations;
  • observational study designs;
  • differences in duration and pressure;
  • inconsistent outcome measures; and
  • substantial risk of bias.

Interestingly, prolonged distension appeared in some studies to produce longer-lasting responses, but this potentially comes at the cost of greater risk of serious complications, particularly bladder perforation.

This creates something of a therapeutic tightrope: more aggressive distension might theoretically produce a greater effect, but pushing harder is not necessarily safer or better.


What about a genuinely small bladder?

A distinction needs to be made between a functionally small bladder and an anatomically contracted bladder.

Functional small bladder

A patient with bladder pain may void frequently at volumes of only 100–200 mL because further filling becomes uncomfortable.

Under anaesthesia, however, the bladder may accommodate a considerably larger volume.

In this situation, hydrodistension may have both diagnostic and therapeutic value.

Anatomically small or fibrotic bladder

Some patients have genuine fibrosis and loss of bladder compliance.

Causes can include:

  • severe longstanding IC/BPS;
  • previous pelvic radiotherapy;
  • chronic inflammatory bladder disease;
  • tuberculosis or other uncommon chronic infections;
  • previous bladder surgery;
  • chemical cystitis; and
  • other causes of bladder fibrosis.

Hydrodistension is much less likely to produce durable enlargement of a severely fibrotic, non-compliant bladder.

Indeed, determining anatomical bladder capacity during hydrodistension can help identify the subgroup of patients whose reduced capacity results from fibrosis rather than simply pain-related early voiding.

Patients with severely contracted bladders therefore require individual assessment rather than repeated attempts to mechanically stretch the bladder.


What are the potential benefits?

For appropriately selected patients, benefits may include:

  • reduced bladder pain;
  • reduced urgency;
  • reduced urinary frequency;
  • improved bladder filling tolerance;
  • increased functional voided volumes;
  • reduced nocturia;
  • improved quality of life;
  • identification of Hunner lesions;
  • determination of true anatomical bladder capacity; and
  • exclusion of other bladder pathology.

Some patients experience substantial improvement and occasionally request repeat hydrodistension when symptoms eventually return.

Others experience little or no improvement.

Unfortunately, there is currently no perfect test that tells us beforehand which patient will fall into which group.


What happens immediately after the procedure?

Temporary worsening of symptoms is relatively common.

For several days patients may experience:

  • burning when passing urine;
  • increased urinary frequency;
  • urgency;
  • bladder discomfort or spasms;
  • pelvic pain; and
  • blood in the urine.

A short-term flare of IC/BPS symptoms can also occur after hydrodistension. This is generally managed with analgesia and supportive treatment.

The bladder has, after all, just undergone considerably more filling than it normally tolerates, so it may complain rather loudly for a short period afterwards.


What are the potential complications?

Most complications are minor and temporary, but patients should understand that more significant complications are possible.

These include:

Haematuria

Blood in the urine is relatively common immediately following the procedure and generally settles spontaneously.

Bladder pain and symptom flare

Paradoxically, the procedure intended to improve bladder pain may initially make it worse.

Symptoms usually settle, but occasionally the flare can be prolonged.

Urinary tract infection

Instrumentation of the urinary tract carries a risk of infection.

Patients developing fever, chills, worsening pain or difficulty passing urine following the procedure should seek medical attention.

Urinary retention

Temporary difficulty emptying the bladder can occasionally occur, particularly following anaesthesia or when additional bladder treatments have been performed.

Temporary catheterisation may be required.

Bladder perforation or rupture

This is uncommon with carefully controlled modern techniques but represents the most important procedural complication.

The risk becomes more concerning when high pressures or prolonged distension are employed.

Anaesthetic complications

Because hydrodistension is generally performed under anaesthesia or sedation, the usual anaesthetic risks also apply.


Why pressure and duration matter

Historical hydrodistension techniques could be considerably more aggressive than contemporary practice.

The American Urological Association has specifically advised against high-pressure, long-duration hydrodistension because it has been associated with serious complications including:

  • bladder rupture;
  • significant bleeding; and
  • sepsis.

High-pressure techniques above approximately 80–100 cm H₂O, particularly when combined with prolonged distension, have not demonstrated sufficiently consistent additional benefit to justify these increased risks.

This is why contemporary treatment should be controlled rather than heroic. The objective is therapeutic distension, not a competition to discover the maximum volume a bladder can tolerate.


Can bladder distension be repeated?

Yes, in selected patients.

If a patient obtains substantial improvement lasting several months, repeat hydrodistension may be considered when symptoms recur.

However, repeated procedures should not simply become an automatic treatment cycle.

The potential benefit needs to be balanced against:

  • repeated anaesthesia;
  • postoperative symptom flares;
  • infection;
  • bleeding;
  • bladder injury;
  • cost and inconvenience; and
  • availability of alternative therapies.

A patient who experienced no meaningful improvement after a properly performed initial hydrodistension is unlikely to benefit from endlessly repeating the same procedure without reconsidering the diagnosis and treatment strategy.


How does hydrodistension fit into modern IC/BPS treatment?

IC/BPS is increasingly regarded as a heterogeneous condition rather than a single disease.

Treatment may therefore include combinations of:

  • dietary and behavioural modification;
  • bladder retraining;
  • pelvic floor physiotherapy;
  • pain management;
  • oral medication;
  • intravesical bladder instillations;
  • treatment of Hunner lesions;
  • hydrodistension;
  • intradetrusor botulinum toxin;
  • neuromodulation; and
  • rarely, major reconstructive surgery for severe refractory disease.

The 2025 Canadian Urological Association guideline, for example, conditionally recommends intradetrusor botulinum toxin, with or without hydrodistension, for selected patients with IC/BPS refractory to other treatments, although the certainty of evidence remains very low.


Hydrodistension combined with Botox

There is increasing interest in combining hydrodistension with intradetrusor botulinum toxin A.

Botulinum toxin may reduce sensory signalling from the bladder as well as detrusor activity.

The EAU guideline cites studies in which patients receiving hydrodistension plus botulinum toxin had more sustained improvement in pain and bladder capacity than patients undergoing hydrodistension alone.

This does not mean Botox is appropriate for every patient. Potential complications include increased residual urine and urinary retention, occasionally requiring intermittent self-catheterisation.


So, does regulated bladder distension actually work?

Yes, for some patients, but not reliably and usually not permanently.

That is probably the fairest interpretation of the current evidence.

Hydrodistension can produce worthwhile improvement in pain, frequency and functional bladder capacity in a subset of patients with IC/BPS. Some patients experience surprisingly prolonged relief.

However:

the response is unpredictable, symptoms commonly recur, and high-quality evidence demonstrating durable long-term benefit remains limited.

The most recent systematic review reached essentially the same conclusion: hydrodistension remains a viable but controversial treatment because studies suggest benefit while the overall quality and consistency of evidence remain insufficient.

The European Association of Urology consequently considers hydrodistension to have a limited therapeutic role, despite its continued use in clinical practice.


The bottom line

Regulated bladder hydrodistension is best viewed as a selective diagnostic and therapeutic procedure rather than a cure for a small or painful bladder.

It may be particularly useful when:

  • IC/BPS symptoms remain troublesome despite conservative treatment;
  • bladder capacity appears markedly reduced;
  • Hunner lesions are suspected;
  • anatomical bladder capacity needs to be established; or
  • cystoscopy is required to exclude another cause for the symptoms.

When performed, a carefully controlled, low-pressure and relatively short-duration technique has traditionally been favoured because aggressive high-pressure distension increases the risk of bladder injury without convincing evidence of superior benefit.

For patients with a genuinely scarred, contracted and poorly compliant bladder, however, hydrodistension should not be expected to magically restore normal bladder capacity. These patients may require a different and more individualised management strategy.

Ultimately, the question is not simply:

“Can the bladder be stretched?”

It is:

“Why is this bladder small or painful, and is controlled distension likely to change the underlying problem?”

That distinction is central to selecting the patients most likely to benefit.

Research and guideline references

  1. Lim S, Alhamdani Z, Qin KR, et al. Optimal Duration of Hydrodistension for Symptomatic Treatment of Interstitial Cystitis: A Systematic Review. Neurourology and Urodynamics. First published 2025. The review included 14 studies and 1,404 patients and highlighted both potential symptomatic benefit and substantial heterogeneity in the evidence.
  2. European Association of Urology. EAU Guidelines on Chronic Pelvic Pain: Primary Bladder Pain Syndrome. Current guidance describes the scientific basis for hydrodistension as limited and its therapeutic role as relatively limited.
  3. American Urological Association. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. Low-pressure, short-duration hydrodistension is described as an option, while high-pressure, prolonged hydrodistension is discouraged because of the increased risk of serious adverse events.
  4. Canadian Urological Association. CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Observational studies reported variable and generally declining response rates following hydrodistension.
  5. Canadian Urological Association. 2025 CUA Guideline: Selected treatment recommendations for interstitial cystitis/bladder pain syndrome. Discusses contemporary treatment options including intradetrusor botulinum toxin with or without hydrodistension in refractory IC/BPS.
  6. Malde S, Palmisani S, Al-Kaisy A, Sahai A. Guideline of guidelines: bladder pain syndrome. BJU International. 2018. The review highlights substantial variation between international recommendations and the limited evidence supporting hydrodistension as a long-term therapeutic strategy.

This information is intended for general patient education and does not replace individual assessment by a urologist. The appropriateness and technique of bladder hydrodistension should be determined according to the underlying diagnosis, bladder characteristics, previous treatments and individual patient circumstances.

So, come see your local Brisbane Urologist, Uro-Jo to discuss this option.

Upper Tract Urothelial Carcinoma

Cancer of the Renal Pelvis and Ureter

Urothelial carcinoma is most commonly associated with the bladder, but the same specialised lining extends all the way from the bladder up the ureters and into the collecting system of each kidney.

When a urothelial cancer develops in the renal pelvis or ureter, it is called upper tract urothelial carcinoma (UTUC).

UTUC is considerably less common than bladder cancer. Importantly, its behaviour varies enormously. Some tumours are small, superficial and relatively slow growing, while others are aggressive cancers capable of invading the kidney, surrounding tissues, lymph nodes and distant organs.

The key to successful management is therefore not simply finding the tumour, but determining how aggressive it is and how likely it is to spread.


What Is the Upper Urinary Tract?

Urine produced by the kidney drains through:

Kidney → renal calyces → renal pelvis → ureter → bladder → urethra

The inner surface of the renal pelvis, ureter and bladder is covered by urothelium, previously called transitional epithelium.

Cancer arising from these cells is called urothelial carcinoma.

UTUC can therefore occur in:

  • the renal pelvis;
  • one or more renal calyces;
  • the upper, middle or lower ureter;
  • multiple areas of the same urinary tract; or
  • occasionally both upper urinary tracts.

Patients with UTUC may also develop urothelial tumours within the bladder, either at the same time or later.


What Causes Upper Tract Urothelial Cancer?

Cancer develops when genetic damage accumulates within urothelial cells, allowing them to grow and divide abnormally.

Frequently there is no single identifiable cause, but several important risk factors are recognised.

Smoking

Cigarette smoking is one of the most important preventable risk factors for urothelial carcinoma.

Carcinogenic chemicals absorbed through the lungs enter the bloodstream, are filtered by the kidneys and become concentrated in the urine. The urothelium may therefore be exposed to these substances for many years.

Stopping smoking remains important even after diagnosis because of its wider health benefits and potential relevance to future urothelial cancer risk.

Previous bladder cancer

Patients who have previously had urothelial carcinoma of the bladder have an increased risk of developing urothelial carcinoma elsewhere within the urinary tract.

Similarly, patients treated for UTUC remain at risk of subsequently developing bladder cancer.

Occupational chemical exposure

Long-term exposure to certain industrial chemicals, particularly some aromatic amines historically associated with dye, rubber, textile, leather and chemical industries, has been associated with urothelial cancer.

Lynch syndrome

A small but important proportion of UTUC occurs in people with Lynch syndrome, an inherited disorder caused by abnormalities in DNA mismatch-repair genes.

UTUC, particularly in a younger patient or someone with a strong family history of bowel, endometrial or other Lynch-associated cancers, may prompt consideration of genetic assessment.

Chronic inflammation

Long-standing urinary tract inflammation and some chronic infections may contribute to malignant change. Chronic stone disease has particularly been associated with squamous carcinoma of the renal pelvis, which is a different and much less common tumour type.

Previous analgesic exposure

Heavy historical exposure to certain analgesics, particularly phenacetin-containing preparations that are no longer routinely used in many countries, has been associated with upper tract urothelial malignancy.


What Are the Symptoms?

Blood in the urine

The most common warning sign is:

Haematuria: blood in the urine

This may be obvious, turning the urine pink, red or occasionally dark brown.

Importantly, haematuria may:

  • occur only once;
  • disappear for weeks or months;
  • be completely painless; or
  • only be detected microscopically on a urine test.

Visible blood in the urine should always be appropriately investigated, particularly in adults.

Do not assume that painless bleeding is simply due to infection, prostate enlargement or a blood-thinning medication without appropriate assessment.


Flank or loin pain

A tumour can obstruct drainage of urine from the kidney.

This may produce:

  • persistent flank discomfort;
  • loin pain;
  • renal colic;
  • hydronephrosis, where the kidney becomes dilated because urine cannot drain normally.

Blood clots passing down the ureter can occasionally produce severe colicky pain resembling a kidney stone.


Recurrent urinary symptoms

Some patients experience:

  • urinary frequency;
  • urgency;
  • burning when passing urine;
  • recurrent apparent urinary tract infections.

These symptoms are much more commonly caused by benign conditions, but persistent or unexplained symptoms may warrant further investigation.


General symptoms

More advanced disease can occasionally cause:

  • unexplained weight loss;
  • loss of appetite;
  • fatigue;
  • persistent pain;
  • anaemia.

Fortunately, many tumours are detected before these symptoms develop.


How Is UTUC Diagnosed?

Investigation usually involves several complementary tests.

1. Urine testing

Urine is assessed for:

  • microscopic blood;
  • infection;
  • renal abnormalities; and
  • sometimes malignant cells.

Urine cytology

Urine cytology examines shed urinary cells under a microscope.

It is particularly useful for detecting high-grade urothelial carcinoma, although a negative cytology result does not completely exclude cancer.

Selective urine samples may sometimes be collected directly from the affected upper urinary tract.


2. CT Urography

CT urography is one of the most important imaging investigations for suspected UTUC.

Contrast-enhanced CT imaging allows assessment of:

  • the kidneys;
  • renal collecting systems;
  • ureters;
  • bladder;
  • lymph nodes; and
  • surrounding organs.

A tumour may appear as a filling defect, thickening of the ureter or renal pelvis, or an infiltrating mass.

CT can also identify obstruction and hydronephrosis.


3. Cystoscopy

Because urothelial cancer can occur at more than one location, the bladder should generally also be examined.

A flexible cystoscope is passed through the urethra into the bladder to look for associated bladder tumours.


Ureteroscopy and Biopsy

Sometimes imaging alone cannot provide enough information about the tumour.

A ureteroscope is a very fine telescope passed through the urethra and bladder and then into the ureter and renal collecting system.

This allows the urologist to directly inspect the tumour.

During ureteroscopy it may be possible to:

  • identify the location of the tumour;
  • assess whether there is one tumour or several;
  • estimate its size;
  • obtain selective urine cytology;
  • take a biopsy; and
  • in selected low-risk tumours, treat the lesion with a laser.

Biopsy is particularly helpful in determining whether the tumour is low-grade or high-grade.

An important limitation is that ureteroscopic biopsy samples are small, so determining the exact depth of invasion before definitive surgery can sometimes be difficult.


Low-Risk Versus High-Risk Disease

Modern management increasingly divides UTUC according to its risk of invasion and progression.

Factors considered include:

  • tumour grade;
  • appearance on CT;
  • tumour size;
  • number of tumours;
  • presence of hydronephrosis;
  • urine cytology;
  • ureteroscopic appearance;
  • biopsy findings;
  • evidence of invasion; and
  • previous urothelial cancer.

This distinction is extremely important because treatment can range from relatively conservative endoscopic therapy to removal of the entire kidney and ureter.


Treatment of Low-Risk UTUC

Selected patients with low-risk disease may be suitable for kidney-sparing treatment.

The objective is to control the cancer while preserving as much functioning kidney tissue as possible.

Ureteroscopic Laser Treatment

A ureteroscope is passed to the tumour and the lesion is treated using laser energy.

Laser treatment can:

  • vaporise;
  • coagulate; or
  • fragment the tumour.

Modern flexible ureteroscopes allow access to much of the renal collecting system.

Advantages

Kidney-sparing treatment may:

  • preserve kidney function;
  • avoid major abdominal surgery;
  • reduce recovery time;
  • be particularly valuable in patients with impaired kidney function or a solitary kidney.

Disadvantages

The trade-off is the need for very careful surveillance.

UTUC has a tendency to recur, so patients may require repeated:

  • ureteroscopy;
  • urine cytology;
  • CT imaging; and
  • occasionally further laser treatments or biopsies.

Kidney preservation therefore does not mean that the tumour can simply be treated once and forgotten.


Segmental Ureterectomy

Some tumours confined to a relatively short section of ureter can be treated by removing only the affected portion.

This is known as segmental ureterectomy.

It is particularly useful for appropriately selected tumours of the distal ureter.

The affected segment is removed and the remaining ureter is either reconnected or reimplanted into the bladder.

This can preserve the kidney while providing a complete surgical specimen for pathological examination.


Treatment of High-Risk UTUC

For patients with high-risk localised disease, the standard definitive operation is generally:

Radical Nephroureterectomy

This involves removal of:

the kidney + entire ureter + a cuff of bladder surrounding the ureteric opening

Removing the complete ureter is important because leaving part of the affected ureter behind may allow cancer to recur within the remaining urothelium.

The procedure can often be performed using:

  • robotic surgery;
  • laparoscopic surgery; or
  • occasionally open surgery.

The choice depends upon tumour characteristics, anatomy, previous surgery and individual circumstances.


What About the Lymph Nodes?

For selected high-risk tumours, lymph nodes draining the affected area may also be removed.

A lymph-node dissection can provide important staging information and may be incorporated into the surgical management of appropriately selected high-risk disease.


Chemotherapy

Systemic chemotherapy plays an important role in selected patients with higher-risk UTUC.

Platinum-based chemotherapy, particularly cisplatin-containing treatment, has traditionally formed an important part of systemic treatment.

Chemotherapy may be given:

Before surgery: neoadjuvant chemotherapy

One potential advantage is that both kidneys are still present, and renal function may therefore be better able to tolerate cisplatin.

After surgery: adjuvant chemotherapy

Chemotherapy may be recommended after nephroureterectomy when the final pathology demonstrates sufficiently high-risk disease.

An important consideration is that removing a kidney can reduce renal function, potentially affecting the patient’s ability to receive certain chemotherapy drugs.

Treatment decisions are therefore ideally made by a multidisciplinary uro-oncology team.


Immunotherapy and Newer Treatments

The treatment of advanced urothelial carcinoma has changed considerably in recent years.

Depending upon the stage, previous treatment and molecular characteristics of the cancer, systemic therapy may include combinations of:

  • platinum-based chemotherapy;
  • immune checkpoint inhibitors;
  • antibody-drug conjugates; and
  • targeted treatments for selected molecular abnormalities such as FGFR alterations.

These treatments are particularly relevant to patients with locally advanced, recurrent or metastatic disease.

Treatment is increasingly individualised according to the biological characteristics of the tumour and the patient’s kidney function and overall health.


Treatment Placed Directly Into the Upper Urinary Tract

For carefully selected non-invasive disease, medication may sometimes be delivered directly into the renal pelvis and ureter.

Options can include topical chemotherapy or immunotherapy in selected circumstances.

A chemoablative gel formulation of mitomycin has also been developed for selected low-grade UTUC, allowing prolonged contact between chemotherapy and the tumour.

These treatments are specialised and are not suitable for every patient.


What Happens After Treatment?

Follow-up is particularly important because urothelial carcinoma has a characteristic ability to develop at another point along the urinary tract.

After treatment, surveillance may include:

  • cystoscopy;
  • urine cytology;
  • CT urography or other upper-tract imaging;
  • blood tests to assess kidney function;
  • ureteroscopy following kidney-sparing treatment.

The exact surveillance schedule depends upon whether the original tumour was low or high risk and what treatment was performed.


Can the Cancer Return in the Bladder?

Yes.

One of the distinctive features of UTUC is the significant risk of subsequently developing urothelial carcinoma within the bladder.

Published data have reported subsequent bladder tumours in a substantial proportion of patients following treatment of UTUC.

For this reason, regular cystoscopic surveillance remains important even when the original kidney or ureteric tumour has been completely removed.


What Is the Prognosis?

The outlook for UTUC depends predominantly upon:

  • tumour stage;
  • tumour grade;
  • lymph-node involvement;
  • metastatic spread;
  • tumour multifocality;
  • response to treatment; and
  • certain pathological and molecular characteristics.

The most important question is whether the cancer remains superficial or has invaded deeply through the wall of the renal pelvis or ureter.

Superficial, localised disease

The outlook can be excellent when a tumour is identified while still superficial and confined to the upper urinary tract. The National Cancer Institute reports that more than 90% of superficial cancers confined to the renal pelvis or ureter may be curable.

Invasive disease

Once a tumour has invaded deeply into the wall or surrounding tissues, the risk of lymph-node involvement and distant spread increases substantially.

High-grade and invasive tumours therefore usually require more aggressive treatment and closer surveillance.

Metastatic disease

When UTUC has spread to distant organs, treatment is generally systemic rather than surgical alone.

Although metastatic UTUC remains a serious disease, modern systemic treatments have expanded considerably and can provide meaningful cancer control for selected patients.


UTUC and Kidney Function

Preserving kidney function is an important part of treatment planning.

Removing one kidney is usually well tolerated when the opposite kidney is healthy, but kidney function can become particularly important in patients with:

  • pre-existing chronic kidney disease;
  • diabetes;
  • hypertension;
  • a solitary kidney;
  • bilateral upper-tract tumours; or
  • conditions likely to affect future kidney function.

The decision between kidney-sparing treatment and radical nephroureterectomy therefore involves balancing two priorities:

adequate cancer control and preservation of renal function.

Cancer safety remains the priority, but in appropriately selected low-risk disease these objectives can often coexist.


When Should You See a Urologist?

Seek medical assessment if you develop:

  • visible blood in the urine;
  • persistent microscopic haematuria;
  • unexplained flank or loin pain;
  • recurrent unexplained urinary symptoms;
  • abnormal findings on kidney imaging; or
  • haematuria with a previous history of urothelial cancer.

Blood in the urine should not automatically be attributed to prostate enlargement, infection, kidney stones or blood-thinning medication without appropriate investigation.


The Bottom Line

Upper tract urothelial carcinoma is an uncommon cancer arising from the lining of the renal pelvis or ureter.

Blood in the urine is its most important warning sign.

Investigation commonly involves CT urography, cystoscopy, urine cytology and, when required, ureteroscopy with biopsy.

Treatment is increasingly tailored to the biological risk of the tumour.

Small, low-grade tumours may sometimes be managed with kidney-sparing ureteroscopic laser treatment or segmental surgery, while high-risk invasive cancers generally require radical nephroureterectomy with removal of the bladder cuff, sometimes combined with lymph-node surgery and systemic treatment.

Long-term surveillance is essential because urothelial cancer can recur elsewhere within the urinary tract, particularly the bladder.

The reassuring part is that when UTUC is detected while still superficial and localised, the likelihood of successful treatment can be very high.


A Note for Patients

Every upper tract urothelial tumour is different. Treatment depends upon the tumour’s location, size, grade, stage, number of lesions, kidney function and your general health.

Management should therefore be individualised following discussion with your urologist and, for higher-risk disease, a multidisciplinary uro-oncology team.

This information is intended for general patient education and should not replace individual medical advice, examination or treatment recommendations from your treating specialist.

So, if you have any of the above symptoms, come see your local Brisbane Urologsit, Jo at any of my 2 locations, Wesley and Caboolture Hospitals

The current 2026 EAU guideline specifically incorporates updated risk stratification, kidney-sparing management, bladder-cuff and lymph-node considerations, systemic therapy, and follow-up recommendations.

2026 EAU Upper Urinary Tract Urothelial Carcinoma Guideline
National Cancer Institute patient information on renal pelvis and ureter urothelial cancer